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ABSTRACT 
Sarcoidosis is a multisystemic disease of unknown etiology and unpredictable course, 
characterized by histopathological conglomerates of inflammatory cells defined as granulomas.  
These lesions however are non-pathognomonic, and in the absence of an identifiable etiologic 
agent, there are not specific diagnostic test for sarcoidosis. Despite the variable course of 
sarcoidosis, the lungs are affected in 90 percent of the cases.  Approximately 25-30% of 
sarcoidosis patients progress to a complicated phenotype with progressive disease, leading to 
pulmonary fibrosis and organ dysfunction with increased mortality. These cases are in 
desperate need for biomarkers, conventional sarcoidosis biomarkers have proven to be 
insufficiently sensitive for implementation in routine clinical care.  
 In this dissertation, I focused on the use of alternate strategies for biomarkers 
development utilizing genomic base approaches based on high-throughput molecular assays 
to characterize genotype, gene expression, and epigenetics that define sarcoidosis 
subphenotypes. Our results demonstrated that the integration of expression quantitative loci 
(eQTL) studies increase the power of Genome-wide association studies (GWAS). We 
identified SNPs that were associated to complicated sarcoidosis in African Americans (AA) and 
in European Americans (EA), and then we validated these SNPs by Massarray.  Furthermore, 
at the transcript level, we identified the Peripheral Mononuclear Cells (PBMCs) responses to 
TNF-α exposure, a cytokine involved in the initiation of granulomas and   progression of 
fibrosis in sarcoidosis and identified a differential dysregulation in pathways unique to 
complicated sarcoidosis. At the transcriptome level, we profiled microdisected granulomas 
from lung and lymph nodes, and identified a hub of genes that were dysregulated only in 
sarcoidosis in both compartments. Additionally, we compared the genomic profile of these 
granulomas in Sarcoidosis vs Tuberculosis (TB) and Coccidioidomycosis. We corroborated 
that some genes previously suggested as potential sarcoidosis markers were also present in 
fungal or mycobacterium granulomas, pointing to a common mechanistic origin. We also 
demonstrated a strong similarity at the transcriptional level between Sarcoidosis and TB. The 
contribution of the epigenetic mechanisms to the clinical presentation of sarcoidosis was 
assessed through DNA methylation analysis, complicated sarcoidosis reveled a hypo-
methylated pattern in genes within HLA complex while the miRNA analysis derived a molecular 
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signature consisting of 17 protein-coding genes, potentially regulated by 8 miRNAs 
dysregulated in complicated sarcoidosis. 
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Molecular Strategies to Distinguish Key Subphenotypes in Sarcoidosis  
 
 
1. INTRODUCTION 
1.1 Sarcoidosis definition and Historical Context. 
Sarcoidosis is a multisystemic disease of unknown origin and unpredictable course,  
characterized by the formation of granulomatous lesions, especially in the lungs, liver, skin, 
and lymph nodes, with a heterogeneous set of clinical manifestations (1). The clinical course in 
Sarcoidosis is unpredictable and is influenced by granulomatous inflammation that most often 
affects the lungs and intrathoracic lymph nodes but can involve any organ.  
From a historical perspective, J. Hutchinson initially described sarcoidosis as a skin 
disease in coal-warf workers in 1869. A Norwegian clinician, Caesar Boeck, coined the term 
“sarkoid” because the lesion resembled to a benign sarcoma. He later described multiple 
cases of the “benign military lupois” with involvement  of the lungs, conjunctiva, bone lymph 
nodes, spleen and nasal mucous membrane (2). S. Löfgren, a Swedish physician, was the first 
link the triad of biopsy specimens, the erythema nodosum and bilateral hilar adenopathy as 
part of the acute presentations of sarcoidosis, known today as Löfgren’s syndrome.  In was not 
until the 1940’s J.G. Scadding promoted the obtaining of sarcoidosis biopsy, which become the 
most valuable test for sarcoidosis diagnosis until the upcoming of bronchoscopy. With time, it 
became clear that sarcoidosis occurs throughout the world, affecting individuals of both 
genders and all races, although its prevalence varies widely across specific ethnic and racial 
groups(3). 
  
1.2 Sarcoidosis Etiological Factors 
The exact etiology of Sarcoidosis remains to be elucidated.  Sarcoidosis  granulomas are 
histopathological conglomerates of  epithelioid cells, giant cells, CD4+ T cells in the center, 
and CD8 + T lymphocytes and B lymphocytes at their periphery(4). Activated alveolar 
macrophages produce cytokines, chemokines, and various inflammatory mediators, including 
TNF-ά, IL-6, IL-1, IL-12, IL-16, IL-8, MIP-1, RANTES (CCL5), MCP-1 (CCL3), and IP-10.  With 
recruitment of additional monocytes and lymphocytes to the lung, macrophage differentiation 
into epithelioid and multinucleated giant cells, a granuloma is formed. 
These lesions, however are non-pathognomonic, and in the absence of an identifiable 
etiologic agent, are not diagnostic of sarcoidosis or any other specific disease.  Diseases to be 
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excluded include mycobacterial, fungal, and parasitic infections, chronic beryllium disease and 
other pneumoconiosis, hypersensitivity pneumonitis, and Wegener's granulomatosis.  
Pathologists have tried to characterize the granuloma origin based of the histological 
appearance, prototypical examples of necrotizing granulomas are seen with mycobacterial 
infections and non-necrotizing granulomas with sarcoidosis. However, broad differential 
diagnoses exist within each category(5), and it is not unusual that the granulomas of 
sarcoidosis may exhibit focal necrosis of minimal extent. It is has been established that in 
cases with granulomas that exhibit a greater degree of necrosis an infectious or other non-
sarcoidosis related etiology should be strongly suspected(6). While granulomatous 
inflammation may or may not have an infectious etiology, independent molecular and 
immunologic investigations for multiple pathogens as potential etiologic agents including 
pathogenic mycobacteria are require in sarcoidosis (1) due to the histologic similarity between 
tuberculosis and sarcoidosis (7).   Human metagenomics has provided insight into the complex 
composition of the microbiome of several body sites, and this information has allowed 
investigators to draw hypothesis about the relationship between specific microbiomes and 
health (8-12). 
 The Kveim–Siltzbach reaction, a local delayed granulomatous response to the intradermal 
inoculation of sarcoidosis splenic or lymph node tissue, indicates transmissibility of 
sarcoidosis, however the identification of specific antigens in the Kveim reagent that induce a 
sarcoid-like reaction has not been accomplished yet (13). Multiple researchers have attempted 
with limited success to identify microbial lineages in sarcoidosis.  Propionibacteria and 
mycobacteria have been identified as targets of the sarcoidosis BAL-derived adaptive immune 
response (4-7). Mycobacteriophages have been isolated from sarcoidosis granulomas, as well 
as other human specimens with granulomatous inflammation. Despite the evidence of 
mycobacterial infection in some tissue biopsies and peripheral mononuclear cells (PBMCs), 
IgG anti MKat positive ESAT-6 and KatG peptides (14, 15), there is insufficient evidence to 
prove mycobacteria as the etiological agent in sarcoidosis.   Propionibacterium acnes, a 
normal commensal of the skin flora is another candidate organism proposed in sarcoidosis, 
Propionibacterium DNA is present in lymph nodes of Japanese and European patients with 
sarcoidosis in higher proportions than DNA from mycobacteria spp (16, 17), this association 
reported among Japanese subjects, (18, 19) that has not been replicated in American 
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sarcoidosis subjects. Interestingly, some of these antigens cause granulomatous inflammation 
in animals (20, 21).  
The Genomic Research Alpha 1 Antitrypsin deficiency and Sarcoidosis (GRADS) network, 
from which the mentor (site PI) and the candidate were participants, aimed to analyze the 
patterns in the lung microbiome are characteristic of sarcoidosis phenotypes and are reflected 
in changes in systemic inflammatory responses as measured by peripheral blood changes in 
gene transcription(22). Investigators have identified  Th-1 immune responses to mycobacterial 
virulence factors, ESAT-6, katG, Ag85A, and superoxide dismutase A in sarcoidosis  in 
peripheral blood mononuclear cells (PBMC), compared to controls as well as responses to 
these same virulence factors in bronchoalveolar lavage (BAL) (23, 24).   
Other studies suggest that an active infection is not part of sarcoidosis pathobiology, but 
that sarcoidosis results from a host response to tissue antigens associated with an aberrant 
innate response involving serum amyloid A (SAA). (25)  In this  model, progressive 
accumulation of SAA aggregates within sarcoidosis granulomas and results in feed-forward 
amplification of local Th1 responses to tissue antigens, including those from remnant microbial 
antigens from prior infections associated with immune control ((26). Other potential pathogens 
such as viruses have been implicated but its correlation has been inconclusive.  A Case 
Control Etiologic Study of Sarcoidosis (ACCESS) multicenter research group, a multicenter 
designed to determine the etiology of sarcoidosis also tried unsuccessfully to identify wall 
deficient forms of mycobacteria from blood in sarcoidosis patients, however, it provided 
evidence that certain environmental and occupational exposures modestly increase the risk for 
developing sarcoidosis (27). In this regard, environmental and occupational studies 
hypothesized that sarcoidosis may be caused by a dysregulated immune response to 
nanoparticles derived from common metals and minerals in the environment.  To support this,  
recently, a study reported an increased risk of developing sarcoidosis in construction works 
exposed to silica(28). Also, of interest is the histopathological and immunological similarity 
between beryllium exposure and sarcoidosis.  Following the collapse of the World Trade 
Center on September 2011, multiple reports associated the dust exposure  and the 
development of sarcoidosis or  "sarcoid-like" granulomatous pulmonary disease in first 
responders(29, 30) Recent geoepidemiological and occupational research have evaluated 
these combined effects, and identified certain risk occupations (31) and emphasized the 
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genetic individual composition or ethnicity-driven variations. This additive factor influences the 
frequency, epidemiology, clinical expression and outcome of sarcoidosis.   
Many studies (32-35)  indicate genetic factors as a contributory effect to the development 
of sarcoidosis involving an aberrant immune response triggered by an unidentified antigen in 
genetically susceptible individuals. To support the evidence of a dysfunctional genetic 
mechanism, there have been reported familiar clustering of sarcoidosis; studies have 
demonstrated an increased incidence of sarcoidosis in monozygotic twins (36).  Furthermore, 
ethnicity heavily influences the clinical phenotype by modifying the age at diagnosis and the 
rates of thoracic and extra thoracic involvements. The highest incidence rates are uniformly 
reported in the United Stated for Black/African-American people, independently of the 
geographical location, with rates between 2- and 10-fold higher than those reported in White 
people living in the same geographical area (37). Significant racial and gender disparities exist 
in sarcoidosis development and prognosis in the U.S., with highest incidence in African 
American women(38).  Furthermore, the interactions between changes in systemic 
inflammation and individual genomic composition that may influence the heterogeneity of 
disease phenotypes are not well understood 
 
1.3 Sarcoidosis Clinical Presentation and Staging. 
Despite significant progress in the understanding of the genetic predisposition and role of 
immunity, it is still a challenge to explain the clinical presentation of sarcoidosis. The diagnosis 
of sarcoidosis is further hindered by the lack of any reliable and specific diagnostic test, as 
there are no laboratory or imaging findings that enable the definitive diagnosis of sarcoidosis 
Usually the diagnosis is established when characteristic clinical-radiological features are 
supported by compatible histopathology of epithelioid cell granulomas, following exclusion of 
known causes of granulomatous inflammation (3, 13). 
Non-specific constitutional symptoms such as fever, fatigue, malaise, and weight loss may 
occur in about one-third of patients with sarcoidosis. Most patients with pulmonary sarcoidosis 
recover spontaneously, whereas a significant number of patients exhibit progressive disease 
leading to varying degrees of pulmonary fibrosis.  Standard clinical assessment, imaging, and 
pulmonary function tests (PFTs) do not allow prediction of disease course and response to 
therapy. However, a correlation with the mode of the onset and the extent of the disease has 
been observed. Most patients are middle-aged adults and frequently present with bilateral hilar 
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lymphadenopathy, pulmonary infiltration and ocular and skin lesions. Although not very 
common, Löfgren   syndrome an acute well characterized presentation   of sarcoidosis, is 
differentiated by the presence of erythema nodosum, an acute nodular panniculitis that affects 
the lower legs, BHL, and polyarthralgia. It  is associated with spontaneous regression or 
usually heralds a self-limiting course, whereas an insidious onset, especially with multiple 
extrapulmonary lesions, may be followed by relentless, progressive fibrosis of the lungs and 
other organs(13). Ocular and skin lesions may become sight threatening or disfiguring thereby 
requiring aggressive treatment. Cardiac and neurologic involvement may cause morbidity and 
death. 
Despite the variable course of sarcoidosis the lung is affected in 90% of cases but also may 
affect other organs (39). A classification based on intrathoracic radiographic changes, the 
Scadding Classification has been proposed (13) with the majority (50-60%) of  sarcoidosis 
patients categorized at  stage I with hilar and mediastinal lymphadenopathy, but without lung 
involvement (Table 1) . Stage II is defined as hilar lymphadenopathy with lung infiltrates. 
Frequently, at this stage patients will experience spontaneous remission whereas remission 
will occur in only 10-20% of individuals with Stage III which is characterized by the presence of 
diffuse interstitial infiltrates, without lymphadenopathy. Patients with Stage IV disease rarely 
have remissions after the development of pulmonary fibrosis and honeycombing (Stage IV). 
(Table 1). 
 
TABLE 1. Chest Radiographic Stages of Sarcoidosis 
Stage Finding 
0 Normal chest radiograph 
I Bilateral hilar lymphadenopathy (BHL) 
II BHL plus pulmonary infiltrations 
III Pulmonary infiltrations (without BHL) 
IV Pulmonary fibrosis 
  
 
Greater  than   50%   of sarcoidosis patients will  experience  remission  within  3  years  after  
diagnosis,  with  over 66%  of  patients  experiencing  remission  within  10  years(40). While 
certain disease phenotypes and chest radiograph stages portend a good prognosis, a large 
   
15 
 
proportion of patients would benefit from technological advances in biomarker development 
that would allow for identification of individuals at risk for increased severity of disease and the 
potential initiation of immunological therapies 
 
1.4 Simple vs Complicated Sarcoidosis 
In the absence of predictive biomarkers, clinical stratification of sarcoidosis remains a 
significant challenge. There are two major classifications of sarcoidosis severity based on 
disease evolution simple vs complicated. Patients with simple or uncomplicated sarcoidosis, 
typically  asymptomatic stage I or II, tend to either experience spontaneous resolution or 
recover completely in up to 70- 90% of cases (41). In certain cases, the initial presentation of 
sarcoidosis is cutaneous and self-limited, exhibiting papules, ulcers, ichthyosis to erythema 
nodosum, a non-granulomatous panniculitis that usually occurs in acute sarcoidosis, and lupus 
pernio, a disfiguring red-to-purple plaques and nodules on the nose and cheeks. 
Epidemiological studies suggest that when cutaneous sarcoidosis associated to systemic 
symptoms require systemic work out to monitor closely the progression to multiorgan 
involvement (42). In general sarcoidosis morbidity tends to be more severe in black patients, 
whereas, white patients are more likely to have spontaneous resolution (43).  
Approximately 25-30% of sarcoidosis patients exhibit a complicated sarcoidosis phenotype 
(Table 2) with progressive disease leading to varying degrees of pulmonary fibrosis and organ 
dysfunction (heart, neurological, etc.)  with increased mortality(44). Table 2 depicts criteria our 
research group has utilized to categorize sarcoidosis subphenotypes.  Our research group 
proposed the following criteria to stratify complicated sarcoidosis, it consolidates imaging 
(radiographic and CT scan) classification, pulmonary function test (Forced Vital Capacity) and 
involvement to vital organs(45) Table 2. 
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TABLE 2. Sarcoidosis clinically defined phenotype 
  
 Complicated Sarcoidosis           
 
Lung involvement:  Documented parenchymal lung disease by CT scan,  
        radiographic stages III and IV and/or PFT with FVC <50%.   
Organ involvement: Cardiac or neurological involvement in addition to the lungs. 
 
Uncomplicated Sarcoidosis         
Skin or pulmonary involvement limited to the mediastinal lymphadenopathy  
        documented by CT or radiographic stages I and II.       
This table was originally published in Scientific Reports by T. Zhou and N. Casanova (2017) (46). 
  
 The clinical manifestations and disease course of sarcoidosis are both variable and 
largely unpredictable; from acute presentations with systemic symptoms that spontaneously 
remit without requiring immunosuppression, to relapsing and remitting disease that can lead to 
significant organ dysfunction over time, to chronic disease requiring long-term 
immunosuppression.  To date there are not curative or effective treatments that reverse the 
course of the disease or that can modify the disease course. Therapeutic approaches such as 
corticosteroids, remain the first line of treatment, and are designed to suppress inflammation. 
While steroids can affect short-and intermediate-term improvement of sarcoidosis, particularly 
in early stage disease, there is little evidence these agents favorably alter long-term outcomes 
of patients with more advanced disease.  
To avoid the side effects of long-term corticosteroids, new disease-modifiers such anti-
TNF agents such as infliximab have been beneficial in limited number of patients, and are 
associated with considerable toxicities (47, 48). In addition, TNF-α blockers increase the risk of 
granulomatous and intracellular infections (49, 50).   
 
 1.5 Challenges in Mechanistic Investigation in Sarcoidosis: Absence of Preclinical 
Models. 
In contrast to other interstitial lung diseases, such as pulmonary fibrosis, a well-accepted 
preclinical model of sarcoidosis is absent.  Sarcoidosis’ lack of a preclinical model has limited 
the study of potential etiological and histological features, the reproducibility and use of new 
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therapeutic targets and biomarkers. Therefore, the research to address these unmet needs is 
markedly hindered.  Multiple attempts have derived in inconclusive models, as one example is, 
Crohn’s disease, another granulomatous noninfectious disease considered as a possible model 
for basic research on sarcoidosis. However, there are no animal models that completely simulate 
the disease process of Crohn's disease(13). Another proposed model   considers multiwall 
carbon nanotube (MWCNT)-based murine model for granulomatous inflammation researchers 
have used this model to compare inflammatory transcriptome signal similarities to BAL 
sarcoidosis in humans (51). 
Recently, the Foundation of Sarcoidosis Research (FSR) sponsored projects for the 
development of novel experimental models for sarcoidosis. One of them based on the 
formation of granuloma-like structures in peripheral blood mononuclear (PBMCs) when these 
cells are challenged with immunogenic tuberculosis antigens, such as purified protein 
derivative (PPD).  Other models include, murine model using Type I IFN activation to 
potentiate granuloma formation following administration of trehalose-6,6´-dimycolate (TDM), a 
lipid found in the cell wall of Mycobacterium tuberculosis. In addition to in silico multi-scale 
computational model of sarcoidosis using transcriptomics and flow cytometry and a model to 
study  lung microenvironment in fibrotic pulmonary sarcoidosis employing culture scaffolds 
from decellularized lung tissues(52).  
Further research is required to elucidate the destructive tissue inflammatory response that 
occurs with the granuloma formation, to identify which factors are responsible for accumulation 
of destructive T cells and monocytes in organs and how best to target therapies that will block 
the chronic and multisystemic response that occurs in sarcoidosis.  
 
2. PRIOR BIOMARKER STUDIES  IN SARCOIDOSIS. 
Portions of this section were originally published in Clinics in Chest Med. Casanova N, 
Zhou T, Knox KS, Garcia JGN. Identifying Novel Biomarkers in Sarcoidosis Using 
Genome-Based Approaches. Clin Chest Med. 2015 Dec;36(4):621-630.  
  2.1 Traditional Blood Biomarkers in Sarcoidosis. The  need  to  develop  useful  
biomarkers  in  the  diagnosis  and  prognosis  of subjects  with  sarcoidosis  has  long  been  
recognized  as  sarcoidosis  is a  diagnosis  of exclusion and  may  mimic  multiple  other  
rheumatologic  illnesses(53, 54). Furthermore, a significant percentage of patients with 
sarcoidosis (~ a third) develop complications with granulomatous involvement of vital organs 
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with progressive disease. Thus, monitoring subclinical disease activity and likelihood of 
progression or remission in a longitudinal fashion remains an important but challenging goal. 
Recently, we review traditional biomarkers in sarcoidosis as well as biomarkers emerging from 
technology-driven strategies (55). Despite limitations, the use of biomarkers to support 
diagnosis and predict disease activity remains a focal point in routine clinical care. Multiple 
methodologies have been applied to detect biomarkers in serum, lung tissue, bronchoalveolar 
lavage fluid (BALF) and exhaled breath condensate (EBC) using enzyme-linked 
immunosorbent assays (ELISA), proteomic analysis and mass spectrometry (56). Traditionally, 
clinical biomarkers measured in sarcoidosis were limited to soluble factors measured in blood, 
BAL or cerebral spinal fluid. Data remains inconsistent regarding the validity of EBC 
biomarkers (57).  As technology improves, biomarker “panels” generated from array data will 
continue to emerge.  
Several potential sarcoidosis biomarkers have been associated with monocyte-
macrophage activation including Angiotensin-Converting Enzyme (ACE), the most 
commonly used biomarker in sarcoidosis. ACE is derived from activated macrophages in 
granulomatous pulmonary remodeling (58), and is useful in supporting a diagnosis and 
monitoring disease activity in some patients (58, 59). ACE levels are increased in approximately 
two-thirds of patients with sarcoidosis with elevated levels reported in neurosarcoidosis (60).  
However, elevated ACE levels are not specific for sarcoidosis, and are observed in 
granulomatous diseases such as tuberculosis, fungal infections, and Gaucher disease (58, 61, 
62). Moreover, there is no evidence that ACE levels significantly differ between active and 
inactive sarcoidosis (59) and do not reliably correlate with the severity of disease (63).Serum 
concentrations at diagnosis were noted to be significantly lower in acute sarcoidosis and in 
Löfgren's syndrome (64). In addition, ACE concentration and activity is influenced by genetic 
polymorphisms with enzymatic activity significantly higher in individuals with the DD genotype 
than in individuals with the II genotype (62, 65, 66). The utility of ACE as a biomarker in diagnosis 
of sarcoidosis remains limited, although future studies utilizing conformational fingerprinting of 
ACE may yield better specificity [73].  While ACE is the prototypic sarcoid biomarker, similar 
conclusions are made regarding other soluble biomarkers outlined below.   
Serum amyloid A (SAA) is an acute phase protein produced in the liver and upregulated 
by monocyte and macrophage-derived cytokines (67). SAA levels were significantly higher in 
sarcoidosis patients than in healthy controls (56, 68, 69) and significantly higher in sarcoidosis 
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patients with active disease (59). However, like ACE, this biomarker suffers from low specificity 
although SAA levels may be more useful during follow-up as SAA levels are less sensitive to 
immunosuppressive drugs, such as corticosteroids. Cytokines such as tumor necrosis factor 
(TNF-α, TNF-β) play a major role in granuloma formation and are released in greater quantities 
from alveolar macrophages obtained from sarcoidosis patients(70).  
Lysozyme is an enzyme produced by macrophages to degrade bacteria and is elevated 
in numerous inflammatory conditions, including sarcoidosis.  Lysozyme historically has been 
associated with extrapulmonary sarcoidosis, particularly uveitis (71) and in a recent study was 
more sensitive than ACE(72). Serum chitotriosidase concentrations were significantly higher 
in advanced (stage 3) sarcoidosis compared to healthy controls, directly correlated with ACE 
levels and were highest in those with persistent disease on therapy [26].  
Among the potential sarcoidosis biomarker associated with lymphocyte origin is 
Interleukin-2 receptor (sIL-2R) whose levels shed from lymphocytes are  increased in active 
sarcoidosis and, similar to ACE levels, may predict response to therapy (62).  Elevated levels 
have been correlated with parenchymal infiltration and lung function (73, 74). Similarly, 
persistently elevated sIL-2R may suggest extrapulmonary manifestations of sarcoidosis (59, 70, 
75). IL-17, an interleukin important in mucosal immunity and autoimmunity, is increased in 
patients with ocular sarcoidosis (76) and in the BAL fluid of patients with Lofgren’s syndrome.  
Biomarkers associated with fibrosis and the extracellular matrix include Tenascin-C, an 
extracellular matrix molecule expressed during wound healing in various tissues, is increased in 
granulomatous sarcoidosis [29] and in BALF in patients with parenchymal infiltration on chest 
radiographs [30]. Transforming growth factor TGF-β1 is associated with tissue healing and 
recruiting of fibroblasts and myofibroblasts to the matrix, with over expression of TGF-β1 fibrosis 
can occur. Significantly higher levels of TGF-β1 and ACE were reported in sarcoidosis patients 
(58). 
Measurement of biomarkers to diagnose and predict remitting or progressive disease 
remains promissory and relevant in the management of sarcoidosis.  Despite a rich history and 
intense study, however, no single soluble biomarker has proven to be sufficiently sensitive and 
specific to be recommended for widespread clinical use. 
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TABLE 3. CONVENTIONAL SARCOIDOSIS BIOMARKERS AND THEIR CLINICAL 
ASSOCIATION. 
Biomarker  Origin and clinical association Reference 
ACE 
Monocyte-macrophage origin.  Acute stage, levels 
influenced by polymorphisms. 
A. Salazar et al (2010), A.D. 
Vorselaars et al  (2015); B. 
Baudin et al (2005);A. 
Pietinalho et al (1999) 
sIL-2R 
Lymphocyte associated. Disease severity, extra-
pulmonary organ involvement. 
A.D. Vorselaars (2015); J. C. 
Grutters et a (2003) 
SAA 
Monocyte-macrophage origin.  Higher level in tissue 
and serum in sarcoidosis.   
A. Salazar et al (2010),  
Alpha 1-
antitrypsin 
(BALF) 
Cytokine associated. Down-regulated only in patients 
without LS.  Associated with spontaneous resolution. 
R.C.Young et al (1973) 
Protocadherin-2 
precursor 
(BALF) 
Cell adhesion. Up-regulated in sarcoidosis across all 
studied phenotypes. 
E. Kiegova (2006) 
Chitotriosidase Monocyte-macrophage origin. Disease progression.  E. Bargagli et al (2008) 
Tenascin-C 
(BALF) 
Fibrosis and ECM associated. Levels correlated with 
infiltrates on chest radiographs in sarcoidosis. 
L. E. Crowley et al (2011) 
IL-17RC 
Lymphocyte associated. Elevated expression in 
retinal tissues. 
W. Wu et al et al (2014) 
TGF-β1 
Fibrosis and ECM related. Associated with pulmonary 
fibrosis. 
H. Ahmadzai et al (2013) 
 
Abbreviations: ACE, angiotensin converting enzyme; sIL-2R, soluble Interleukin-2 receptor; SAA, 
Serum amyloid; LS, Lofgren’s syndrome; BALF, bronchioalveolar lavage fluid; ECM, extracellular matrix  
Adapted from Casanova et al, Clin Chest Med 36, 621-630 (2015). 
 
2.2 Alternate Strategies for Biomarker Development in Sarcoidosis 
Genomic-based biomarkers are different types of biomarkers originating from various 
“omics” technologies that combines genomics, proteomics and metabolomics(77). Recent 
establishment of high-throughput molecular assay technologies, such as single-nucleotide 
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polymorphism (SNP) arrays, gene expression microarrays, and protein arrays, has allowed 
discovery of potential new disease biomarkers. These high-throughput approaches have 
been applied to diseases of unknown cause like sarcoidosis to help understand disease 
pathogenesis (78-80) including identification of disease-associated candidate genes  and 
dysregulated pathways with diagnostic and prognostic applications (81-84). Current 
imaging and clinical tools fail to identify individuals at risk for complicated sarcoidosis.  
  Identification of punctual variations in genomic DNA, has identified single 
nucleotide polymorphisms (SNPs) that are disease (sarcoidosis vs controls) or trait specific 
(complicated vs uncomplicated) and that may be associated to an increased racial disparity 
or poor prognosis.   
Similarly, transcriptomic markers based on RNA expression profiles in peripheral 
blood are the most frequently studied disease-related transcriptomes. Genomic expression 
profiling provides the opportunity to identify those genetic variants that contribute to 
complicated sarcoidosis. They are informative in multiple disease classes including 
cancer(85, 86), autoimmune disease(87, 88), psychiatric disease(89), cerebro-vascular 
disease(90), heart failure (91), transplant rejection after cardiac transplantation(92) and 
sarcoidosis (93).   
Microarray analysis of peripheral blood mononuclear gene expression (PBMC) in 
two independent cohorts with Idiopathic Pulmonary Fibrosis (IPF) identified 2595 genes 
associated with outcome distinguished 2 major clusters of IPF patients with a significant 
difference in survival. Zhou et al., reported a 31-gene signature comprised of T cell 
signaling pathway genes associated with sarcoidosis using genome-wide peripheral blood 
gene expression 20-gene sarcoidosis biomarker signature distinguished sarcoidosis (n = 
39) from healthy controls and served as a molecular signature for complicated sarcoidosis 
(94).  Interestingly, the CTLA4 pathway was most significantly associated with survival in 
the derivation and replication cohorts and SmartChip qRT-PCR confirmed that a decrease 
in PBMC expression of CD28, ITK, ICOS or LCK was predictive of decreased survival in 
patients with IPF compared to those expressing high levels. To determine whether we 
could find a similar signature in sarcoidosis we downloaded the published dataset (93) 
(GSE1907) and demonstrated that T-cell genes distinguished sarcoidosis peripheral blood 
from control and that this difference faded 6 months later. Our analysis demonstrated an 
increase in CD4, CXCR4 and CCR3, and a decrease in expression of CTLA4 markers 
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(CD28, LCK, ICOS) in the blood of patients with active disease. Interestingly – while CCR3 
and CCXCR4 were reduced 6 months later, the decrease in CTLA4 genes persisted.  
 
3. PRIOR GENETIC STUDIES IN SARCOIDOSIS SUSCEPTIBILITY AND SEVERITY  
3.1 Family Genetic Studies in Sarcoidosis (ACCESS). Today’s overwhelming 
evidence indicates that sarcoidosis susceptibility and severity is influenced by genetic 
variations in a population-specific manner (33, 95). Previous familial clustering cases in 
African American patients and Swedish strongly support a genetic basis for the 
heterogeneous phenotype with an increased incidence in monozygotic twins (36, 96).  One 
of the first studies addressing this association was ACCESS (A Case-Control Etiology Study 
of Sarcoidosis) the major goal of ACCESS was to generate hypotheses about the etiology 
of sarcoidosis. Here a significant elevated risk of sarcoidosis was observed among first-and 
second-degree relatives compared with controls in both African Americans and whites (36).  
Despite the familial aggregation and association to genetic polymorphisms another family-
based study in African Americans revealed no association between sarcoidosis 
susceptibility and polymorphisms in the angiotensin converting enzyme, vitamin D receptor, 
and tumor necrosis factor-alpha genes (97).  HLA class II was among the genetic 
sarcoidosis- susceptible regions evaluated in ACCESS, HLA DRB1 alleles were significantly 
differently between cases and controls, DPB1 was associated with sarcoidosis in African 
Americans suggesting that some of the difference in susceptibility to sarcoidosis between 
whites and African Americans depends on the differential expression of the HLA alleles 
(98). Another study derived from ACCESS identified the polymorphisms of the IL-1β, tumor 
necrosis factor (TNF)-α, and the immunoglobulin genes Km and Gm in AA, indicating how 
race heavily influences the clinical phenotype by modifying the age at diagnosis and the 
rates of thoracic and extra thoracic involvements(99).  
 
3.2 Genome-Wide Association Studies. Genome wide association studies 
(GWAS) have been utilized to study the genomic predisposition in sarcoidosis and have led 
to the identification genomic variants associated with sarcoidosis susceptibility or specific 
traits.   The first genome wide association study (GWAS) in sarcoidosis was conducted by 
Hofmann et al (100), using Affymetrix Genome-Wide Human SNP Array 5.0 in a 
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predominant German population. This study identified a nonsynonymous single nucleotide 
polymorphism (SNP), rs1049550, residing in the first of four annexin core domains within 
the gene ANXA11 (annexin A11), which was associated with sarcoidosis susceptibility 
(100), a finding confirmed in an independent case-control study in Czech patients (101) and 
in African and European Americans (32, 102). In a separate GWAS conducted by Hofmann 
et al, a nonsynonymous SNP, rs1040461 in gene RAB23 (RAB23, member RAS oncogene 
family), was associated with sarcoidosis in German population, this association was  
replicated in African Americans but not in European Americans (32). More recently, a 
sarcoidosis GWAS in both African and European Americans, using Illumina HumanOmni1-
Quad array (32), identified a novel sarcoidosis-associated SNP, rs715299, within the intro 
region of the gene NOTCH4 (notch 4) in African Americans but not in European Americans 
(32). The locus of this SNP is close to several MHC Class II genes known to be associated 
with sarcoidosis (103, 104) and within the region of high linkage disequilibrium (105). Using 
stepwise conditional association analyses, it was confirmed that the observed signal within 
NOTCH4 is independent of the SNPs within the MHC Class II genes (32). Recently, the use 
of Whole Exome Sequencing (WES), identified 37 genes that could be putatively linked to a 
pediatric form of sarcoidosis in three familial cases, functional analysis of these genes were 
implicated with IFN-γ and anti-inflammatory cytokine IL-10, leukocyte proliferation, bacterial 
defense, and vesicle-mediated transport (106). 
 
3.3 Epigenetic genome-wide studies (miRNA and DNA Methylation).  
Epigenetic regulation controls the expression of genome specific regions allowing gene 
transcription to be enhanced or repressed through a heritable mechanism.  Epigenetic 
processes, including DNA methylation and histone modification, influence gene expression at 
the level of transcription. Various DNA methyl-binding proteins (MBPs) exist (MBD1, MBD2, 
MBD3, MBD4 and MECP2), they share a related DNA-binding domain and react to the 
methylation status of the DNA in promoter regions influencing deacetylation, another 
epigenetic mechanism. Specific MBPs, such as MBD1 are transcriptional repressors that 
participate in the recruitment of co-repressors and histone deacetylases, others, like MECP2, 
probably the best characterized of the MBD family,  binds methylated CpG via its MBD domain 
and exerts repressive effects on transcription over distances of several hundred base pairs 
(107). DNA methylation studies in sarcoidosis are limited.  One study aimed to study 
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SHOX2 methylation pattern from bronchial aspirates in 523 suspected lung cancer patients, 
which putatively allowed a distinction of malignancy from infectious disease, scleroderma a 
and sarcoidosis. Hypermethylation of SHOX2 was only present in lung cancer tissue (108).  
Other study recently published, analyzed the DNA methylation changes in chronic beryllium 
disease and sarcoidosis,  in progressive versus remitting sarcoidosis, identified  15,215 CpGs 
sites with significant methylation changes, but only 801 of them have greater than 5% 
methylation change, demonstrating that DNA methylation may be of utility in tracking 
progression changes but may suffer from statistical power issues (109). 
Epigenetic regulation also includes RNA-based mechanisms, through the regulation of 
gene expression. The majority of RNA transcripts, do not code for protein, microRNAs 
(miRNAs) are part of these non-coding RNAs they act as posttranscriptional regulators. 
MiRNAs base-pair with target mRNAs to inhibit translation or direct mRNA degradation via the 
RISC complex. The first study profiling miRNA in sarcoidosis was conducted in 2012, using 
genome-wide microarray in lung tissue and PBMCs, identifying a distinct pattern of 
differentially expressed-miRNAs (DE-miRNAs) in both tissues, in both cases targeting 
transforming growth factor (TGFβ)-regulated pathways (110). Recently another study derived 
from ACCESS specimens studied the expression of miRNAs from peripheral blood 
mononuclear cells in sarcoidosis vs controls, identifying eight DE-miRNAs in sarcoidosis and 
two miRNAs (hsa-miR-150 and hsa-miR-342) significantly associated with reduced 
lymphocytes and airflow limitations (111). Another study profiled the miRNA of T regulator cells 
in pulmonary sarcoidosis, identifying miR-155 and miR-223 as disease related miRNAs 
associated to alterations in TLR-2 and  NF-κB signaling pathways (112). Recently we profiled 
microRNA and protein-coding gene expression in peripheral blood mononuclear cells from 70 
subjects with Idiopathic Pulmonary Fibrosis (IPF).  We linked the microRNA/gene expression 
level with the quantitative phenotypic variation in IPF, including diffusing capacity of the lung 
for carbon monoxide and the forced vital capacity percent predicted. We intersected these 
predicted mRNA targets against the microarray-observed 712 differentially expressed protein-
coding genes revealing a total of 22 miRNA-mRNA pair that consisted of 21 unique protein-
coding genes yielding a 21-gene signature Each signature performed well in a validation 
cohort comprised of IPF patients aggregated from distinct patient populations recruited from 
different sites 
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3.4 Expression Quantitative Loci (eQTL) studies. Genome-wide association studies 
(GWAS), have demonstrated that most genetic variants reside in non-coding regions and 
therefore involved in gene regulation, complicating the understanding of the role that such 
variants play in the disease pathogenesis. The study of these variants that influence the 
gene expression are called expression quantitative trail loci (eQTLs) that explains a fraction 
of the genetic variance of a gene expression phenotype(113). These regulatory variants are 
identified as cis or trans  depending on the physical distance they are located from the 
gene they regulate, 1 megabase or > 5 megabases, respectively. Figure 1.   
          
 
Figure 1. eQTL regulation of gene expression. A) Regulatory variants can be eQTL for 
gene 2 in (a) tissue and for gene 1 (b) in a different tissue. B)  Network relationships 
based on cis and trans eQTLs.  Reproduced with permission (Dermitzakis E., Nica et al 
Philos Trans R Soc Lond B Biol Sci. 2013 Jun 19; 368(1620).  
                                                                       
 
Identification of gene networks that are perturbed by susceptibility loci and that, in 
turn lead to disease beyond the susceptibility genes provides a more integral approach to 
study complex disease traits (114). Consequently, new approaches to increase the power 
of GWAS and to understand the functional effects of most GWAS-implicated variants 
involve the integration of expression quantitative loci (eQTL) studies. To provide insight into 
how genes are expressed differently across multiple human tissues and how they are 
regulated, the NIH established the Genotype-Tissue Expression (GTEx) program, the 
eQTLs identified in post mortem donors, are accessible to the scientific community through 
the GTEx database. This publicly available database has generated data from 54 non-
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diseased tissue sites across nearly 1000 individuals, primarily for molecular assays 
including WGS, WES, and RNA-Seq. (Casanova et al. 2020 manuscript in press) (115). 
 
STUDIES PERFORMED BY THE CANDIDATE 
 
4. CURRENT GENE EXPRESSION STRATEGIES IN SARCOIDOSIS 
PHENOTYPING   
4.1 Genome-wide gene expression in PBMCs 
We conducted an exploration to identify genetic variants that confer susceptibility to 
developing sarcoidosis or the development of complicated sarcoidosis. We analyzed the 
genetic risk predisposing to complicated versus uncomplicated sarcoidosis in two different 
racial groups, African Americans (AA) and European Americans (EA) (n=274 and n=239, 
respectively) in an Affymetrix 6.0 GWAS platform. After quality control assessment our data 
set included 209 AA and 193 EA. We identified the top GWAS race-specific, risk 
variants/genes potentially involved in sarcoid pathogenesis and stratified them by race and 
complicated status then we created a list of the top SNPs associated to JAK/STAT pathway 
(Table 4).   However, we noticed our GWAS results were underpowered to identify true 
significant variants.  
 
 
 
 
 
 
 
 
 
 
Therefore, we incorporated eQTL data to our analysis. We intersected the 906,600 
probes from Affymetrix 6.0 GWAS corresponding to 541,309 rs id dbSNPs with eQTLS 
from GTEx Analysis V7, that included the following tissues; Lung, brain, hearth, whole 
blood, skin, spleen, artery and pancreas. Using a logistic model, we run four different 
Table 4. Race-specific, risk variants associated to JAK/STAT pathways 
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comparisons according to race (EA vs AA) and complicated status (complicated vs non-
complicated) and identified the top 50 SNPs from each tissue independently. Each SNP 
pair was evaluated for Linkage Disequilibrium (LD) or the non-random association of 
marker alleles and can arise from marker proximity or from selection bias. 621 unique 
SNPs were identified in total, 285 where in linkage equilibrium while 336 where in LD.   
According to GTEx annotations, the 621 SNPs affect 730 genes. Next, we conducted 
pathway enrichment using these 730 genes through Consensus Pathways 
(http://consensuspathdb.org) and identified an important enrichment with genes part of the 
human leukocyte antigen (HLA) system or complex Table 5, this system encodes the major 
histocompatibility complex (MHC) proteins in humans. These cell-surface proteins are 
responsible for the regulation of the immune system in humans located in chromosome 
6p21. 
 
 
 
 
 
 
 
 
 
 
 
 
 
In addition, our GWAS analysis identified SNPs associated to  JAK/STAT pathway 
(Table 5) and then the intersected eQTL. We first annotated the eQTLs JAK /STAT genes  
 
 
 
 
 
 
 Table 5. Top pathways derived from 730 eQTL derived SNPs. 
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4.2 Exvivo Genome-wide gene expression in PBMCs 
 
Recent advances in genome-wide expression profiling techniques, such as gene 
expression microarray and RNA sequencing, provide opportunities to discover novel disease 
mechanisms. These high-throughput approaches have been applied to diseases of unknown 
cause to help understand disease pathogenesis (78-80) including identification of disease-
associated candidate genes with diagnostic and prognostic applications (81-84).  
Prior studies have shown that transcription patterns measured in blood may be an indirect 
and powerful tool to study inflammatory signals in the diseased organs of sarcoidosis 
patients(116). Furthermore, mRNA species are measurable in both plasma and serum and 
could represent another area of investigation into disease biomarkers. Taken together, blood 
components such as PBMCs are easily obtained and processed and serve as non-invasive 
ways to learn tremendous insights about the biology of sarcoidosis and other diseases with 
systemic manifestations.   
Idiopathic Pulmonary Fibrosis (IPF) and Sarcoidosis are both interstitial lung diseases that 
share some similarities both are of unknown etiology; sarcoidosis pulmonary involvement at 
the end stages also develops pulmonary fibrosis to IPF, both have poor prognosis leaving lung 
transplantation as the only alternative. Recently, we evaluated the PBMC expression profile 
in IPF after the CO exposure during a 12-week treatment.  These studies identified a clear 
CO signature dominated by significant dysregulation of genes in the oxidative phosphorylation 
pathway.  Significant differential expression was  observed when comparing  transcriptome 
from week 12 to week  24 with  gene dysregulation response  that was abolished   after the 
treatment termination.  These findings suggest this signature may serve as a potential genomic 
biomarker for CO exposure and perhaps for titration of dosage to allow precision testing of 
therapies in future low dose CO therapeutic studies in IPF (117). 
The transcriptome for PBMCs in sarcoidosis has been studied previously using 
microarray technologies and PCR. One of the earliest studies conducted in sarcoidosis 
measured  the presence of IFN-gamma transcripts, concluding that mRNA for IFN‐γ is 
significantly associated with stage I disease(118).  Preliminary and published data by the 
candidate‘s mentor investigative team identified via genome expression, using Affymetrix 
Human Exon 1.0 ST Array,  a differentially expressed genes that allowed defining 
uncomplicated from complicated sarcoidosis. The initial analysis set comprised of 1233 genes 
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differentially expressed between AA or EA complicated sarcoidosis cases vs. healthy controls 
was utilized. This analysis generated a 20-gene transcriptomic signature in peripheral blood 
mononuclear cells (PBMCs) that distinguishes sarcoidosis from not only healthy individuals as 
well as uncomplicated sarcoidosis from complicated patients with progressive lung disease, 
cardiac or neurologic sarcoidosis involvement (94). Two genes within the unbiased 20-gene 
signature, HBEGF (heparin-binding EGF-like growth factor) and SAP30 (Sin3A-associated 
protein, 30kDa), were strongly up-regulated in complicated sarcoidosis whereas the remaining 
18 signature genes were down-regulated in complicated sarcoidosis (Figure 2). The non-
targeted 20-gene signature distinguished all sarcoidosis patients from healthy controls with an 
accuracy of 86.0% (sensitivity = 88.2% and specificity = 83.3%). 
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Figure 2. Hierarchical clustering discriminates patients with Sarcoidosis and healthy controls 
and differentiated complicated and non-complicated Sarcoidosis. Panel A. DGE Cluster 1: 
sarcoidosis (n=31), cluster 2:  healthy controls (n=18). Blue represents low gene expression, red is high 
gene expression. Panel B. Heatmap of patients with complicated sarcoidosis and uncomplicated 
sarcoidosis. Panel C. Boxplot of expression of the 20 signature genes. The dark grey points and lines 
indicate the geometric mean of expression in each category. HC: healthy controls; US: uncomplicated 
sarcoidosis; and CS: complicated sarcoidosis. Y-axis: log2-transformed expression values. Reproduced 
with permission (Zhou T. et al, PLoS doi: 10.1371/journal.pone.0044818). 
 
We evaluated the performance of our gene signatures in two different independent 
sarcoidosis blood gene expression datasets. One dataset (GEO - GSE19314) from 
University of California, San Francisco (UCSF) this validated peripheral blood molecular 
gene signature appears to be a valuable biomarker in identifying cases with sarcoidosis and 
predicting risk for complicated sarcoidosis. This gene signature was superior in prediction 
accuracy in each of the AA and EA populations when compared to a second signature 
(UCSF) comprised of genes within the T cell receptor–innate immunity pathway that 
includes genes previously associated with sarcoidosis. It also distinguished sarcoidosis 
patients from idiopathic pulmonary fibrosis (IPF) (94).  
 Gene Set Enrichment Analysis of lung samples with fibrotic pulmonary sarcoidosis 
showed that the gene up-regulated in lung samples obtained from patients with progressive-
fibrotic sarcoidosis comprised predominantly the genes involved in host defense and 
immune responses. Genes overexpressed in patients exhibiting progressive-fibrotic 
sarcoidosis are also significantly enriched for genes up-regulated in hypersensitivity 
pneumonitis, another granulomatous lung diseases but different than those in idiopathic 
pulmonary fibrosis (119). Recently, we published a PBMC microarray (Affymetrix GeneChip 
Human Exon 1.0) derived gene signature in sarcoidosis patients with pulmonary 
hypertension, a common comorbidity associated to progressive lung involvement.  The 
discriminative accuracy of this 18-gene signature was 100% in separating sarcoidosis 
patients with PH from those without it. The total number of DEG between sarcoidosis patient 
with and without Ph were 275. Among the 18 genes, HIST1H4C (encoding histone cluster 1, 
H4c), CACHD1 (encoding cache domain containing 1), STOX1 (encoding storkhead box 1), 
and NRCAM (encoding neuronal cell adhesion molecule) were strongly downregulated in 
   
31 
 
PH patients, whereas the remaining 14 genes were upregulated in PH.  In summary, despite 
the small number of patients included in the study, we have identified a molecular gene 
signature as a potential novel molecular biomarker in the diagnosis of PH in sarcoidosis 
(120). 
 The exact mechanism for the modulation  of  inflammatory-related  gene  expression 
remains unknown. Tumor necrosis factor ( TNF-α , TNF-β) is synthesized by activated 
macrophages and T cells and it has a key role in  macrophage activation, phagosome 
activation, differentiation of monocytes into macrophages, recruitment of neutrophils and 
macrophages, granuloma formation, and maintenance of granuloma integrity (1, 121). Two 
TNFA polymorphisms have been identified in cardiac sarcoidosis, no significant difference 
was noted between the patients with cardiac involvement and those without, concerning the 
-1.031T/C and -238G/A (122). Similarly, TNFA2 (TNF_307 A) polymorphism was associated 
significantly with Lofgren’s syndrome and cardiac sarcoidosis (123). 
 Increasing evidence supports the influence of cytokines such as tumor necrosis factor 
alpha (TNF-α) in the initiation, maintenance of granulomas  and  the  progression  of  
fibrosis. Furthermore, the efficacy of biologic TNF antagonists (etanercept, infliximab, and 
adalimumab) as therapeutic strategies has  been validated  in  refractory  sarcoidosis.  
However,  despite  its  effectiveness,  paradoxical  sarcoidosis-like reactions have been 
reported during anti-TNF therapy and limit these approach in particular at-risk 
patients(124). Recently, the candidate studied the transcriptional effect of TNF-α in an Ex 
vivo model on PBMCs for sarcoidosis patients. 282 TNF-α responsive differentially 
expressed genes (DEGs) were identified in uncomplicated sarcoidosis and 550 TNF-α 
responsive genes in complicated sarcoidosis. Sixty genes were common to both 
uncomplicated and complicated sarcoidosis groups. Figure 3.  
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Figure 3. TNF-α responsive differentially expressed genes (DEGs) in sarcoidosis. (A) Principal 
component analysis on transcripts characterizing the TNF-α response (Red -TNF stimulated, Blue-
untreated). X axis: first component with eigenvalue; Y-axis: second component with eigen values. 
(B) Mean-Difference Plot of TNF-α Expression in Complicated and Non-complicated cases. (C) 
Heatmap of top 100 DEGs in PBMCs of complicated and non-complicated sarcoidosis with and 
without TNF-stimulation and untreated healthy controls. These 100 genes show significantly enrich 
for the JAK-STAT pathway, VEGF, cytokine signaling, MAPK activity and the Immune system. 
 
Pathway analysis identified the TNF-α  related transcripts within pathways significantly 
related to the Immune system (95 DEGs; p <10-E10,); NF-kappa B signaling  (18 DEGs; p<10-
9); Cytokine-cytokine receptor interaction (22 DEGs; p <10-9). Other pathways significantly 
enriched included the, Jak-STAT ; TNF-receptor, Apoptosis, and Toll-Like Receptors (p-value 
<0.01).These analyses also showed a prominent MAPK, NF-kB activation and interferon 
response to TNF-α stimulation that was unique to those PBMCs from complicated sarcoidosis. 
(Table 6). 
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In summary, while the number of patients in this pilot group is limited, this study suggests 
the utility of transcriptomic-paired analysis to identify genotype-specific pathways; 
transcript level responses  to TNF-α exposure in  sarcoidosis; and the capacity to identify 
pathways related to disease severity. 
 
4.3 Selected Gene expression in sarcoidosis granulomatous tissue 
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Sarcoidosis is an extremely heterogeneous disease that affects multiple organs, it 
lacks clinical markers capable to differentiate from genomic markers at different multi-organ 
involvement. Previously published transcriptomic studies from blood, lung and lymph node, 
lacrimal gland, orbital tissue and skin (125-127) have identified other sarcoidosis candidate 
genes, many of them that are tissue specific. Thus, assessment of a multisystemic disease 
as sarcoidosis at different compartmental levels is relevant to identify common dysregulated 
transcripts at different stages and compartments of the disease. 
Our goal in this study was to conduct an evaluation on the differentially expressed genes 
(DEG) in lung and lymph node, the most commonly affected organs in sarcoidosis. The HTG 
EdgeSeq Oncology-biomarker panel consisted of 2,535 probes.  We analyzed 2,430 probes 
that uniquely mapped to single genes excluding all the probes with multiple hits or partial 
hits. Transcripts with a fold change (FC) >2 and a p value <0.01 were deemed differentially 
expressed. We identified 250 significantly dysregulated genes between healthy controls and 
diseased tissues. A total of 138 DEGs were present in sarcoidosis granulomas from lung and 
lymph node with a predominant down regulation most marked in lung, 93% of the transcripts 
were downregulated vs 56 % in the lung.  87 of these 138 DEGs were only dysregulated in 
sarcoidosis Granulomas from lymph node and lung had 10 overlapping dysregulated genes; 
ADAMTS1, CXCL2, HSPB6, ITGA9, NPR1, NR4A1, CCL14, CXCL9, FABP4 and NR1H3, 
while only the six first genes were exclusively dysregulated in sarcoidosis but not in Tb or 
cocci. (Figure 4).  ADAMST1, CXCL2, CXCL9, FABP4 were validated in independent 
microarray sets that were tissue specific (lung and lymph node) (Manuscript under revision). 
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Figure 4. Sarcoidosis dysregulated genes present in lung and lymph node. A) Heatmap 
representing the expression of the six DEGs only present in granulomas from sarcoidosis lung and lymph 
node. B) Box plot of the six transcripts dysregulated in lung and lymph nodes from sarcoidosis. C) Total 
transcripts dysregulated in lung and lymph node. Top six genes in bolded, where present exclusively in 
sarcoidosis the last four were also significantly dysregulated in TB.  
 
Despite the similarities present at the histological level, the granuloma from 
sarcoidosis revealed significant divergence at the genomic level at different compartments.   
Sarcoidosis transcriptome derived from lymph nodes in sarcoidosis delineated a clear 
immunological response, involving leucocyte migration and neutrophil chemotaxis; while a 
structural regenerative response was observed at the lung level characterized by cell 
migration and angiogenesis. The later changes associated to a progressive lung 
involvement. 
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Interestingly, the genes shared between comparisons among the three 
granulomatous diseases all have the same orientation regarding the Fold Change, with the 
exception of two, indicating a common patho-genomic mechanism between the granulomas.   
4.4 Sarcoidosis vs other granulomatous diseases genomic profile 
 Recently, the candidate profiled the gene expression associated with sarcoidosis and 
compare to Coccidioidomycosis (Cocci) and Tuberculosis (TB), to assist in the 
development genomic-based biomarkers specific for sarcoidosis (manuscript under 
revision). Microdisected sections of formalin fixed paraffin-embedded (FFPE) granulomas 
were obtained from the pathology department for RNA sequencing, utilizing an immune-
oncopanel (detailed in the methods section). In this study, the candidate analyzed the 
expression profile in granulomas in two of the most commonly affected tissues in 
sarcoidosis and compare it with the transcriptome from granulomas from TB and cocci, two 
common granulomatous diseases in the Southwest of the United States.   We unveiled the 
transcriptome profile, in cells conforming the granuloma at the time of the diagnosis in 
treatment naïve specimens to unravel the molecular mechanisms that occur at the 
compartment level in sarcoidosis and related to diseases that share a common 
histopathological hallmark. We captured transcriptomic changes occurring within the 
granuloma of these granulomatous diseases by using next generation sequencing 
expression not previously reported before. This method, considered as far more precise for 
measurement of transcripts (20), requires low amount of RNA to obtain expression signal 
in paraffin embedded tissues.  The immune-based transcriptomic profiles of 3,000 genes, 
of micro-dissected granulomas from sarcoidosis was analyzed and compared these 
findings to granulomas from cocci and TB, our comparisons were conducted taking in 
consideration the tissue origin on each granulomatous disease . A total of 138 DEGs were 
present in sarcoidosis granulomas from lung and lymph node with a predominant down 
regulation most marked in lung, 93% of the transcripts were downregulated vs 56 % in the 
lung (Figure 5). 
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Figure 5. Heatmap representing the expression profiles of the DEG from granulomatous 
tissue against healthy controls. A) Sarcoidosis lung., B) Sarcoidosis lymph node., C) Cocci.,  D)  
Tuberculosis lymph node. 
 
Interestingly, the genes shared between comparisons among the three 
granulomatous diseases all have the same orientation regarding the FC, with the exception 
of two, indicating a common patho-genomic mechanism between the granulomas.  
Granulomas from lung Cocci shared a proportionally a smaller number of genes indicating 
a lower level of similarity between Cocci and Sarcoidosis than TB and Sarcoidosis. The 
number of DE genes in each comparison using the same thresholds varied significantly, the 
number of dysregulated genes did not correlate with the number of samples per comparison, 
or the size of the microdissection, suggesting that the granulomas are qualitatively different 
depending on the disease and tissue of origin.  
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We confirmed that transcriptome similitudes and divergences that originate from 
same histopathological formation in three different diseases. This study corroborated that 
some genes previously suggested as potential sarcoidosis markers were also present in 
fungal or mycobacterium granulomas pointing to a common mechanistic origin. We 
demonstrated that granulomas from sarcoidosis share stronger similarity at the 
transcriptional and pathway level with TB than with Cocci.  
The transcriptome analysis of the granulomas in the most frequently affected tissues, 
lung and lymph nodes, fills a crucial gap in our knowledge on gene expression in sarcoidosis.  
We were able to corroborate the expression of previously genomic markers postulated as 
potential biomarkers for sarcoidosis and identify the existence on commonly dysregulated 
genes that are exclusively present in sarcoidosis in both lymph and lung tissue (Manuscript 
under revision).  
 
 
Figure 6.  Results of the differential expression analysis.  Volcano plot of overall gene-based 
differential expression.  Comparisons were disease and tissue specific vs healthy controls. The x-
axis corresponds to the log(base2) of the fold change difference , y-axis corresponds to the negative 
log(base10) of the p-values.  A) Lung cocci, B) Lung Sarcoidosis, C) Lymph Sarcoidosis D) Lymph 
TB. 
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           4.5 Functional Genomics (sarcoidosis dysregulated pathways).  
Pathway analysis was performed to understand the pathways that were modulated 
by the DEG in each disease by compartment. We identified that most of the enriched 
transcripts in Sarcoidosis encoded proteins associated with protein binding, regulation of 
biological processes, and cellular processes. Pathway enrichment comparison between lung 
and lymph nodes in sarcoidosis delineated a clear immunological response, involving 
leucocyte migration and neutrophil chemotaxis; while a structural regenerative response 
was observed at the lung level characterized by cell migration and angiogenesis. We also 
identified common biological pathways that were present in both tissues in sarcoidosis 
Figure 7.  Furthermore, our analysis identified common dysregulated pathways in the three 
disease categories (p <0.006)  
     
 
 
 
Figure 7. Top over representations of DEGs against the pathway databases and the gene ontology. 
The x- axis corresponds to the negative log (base 10) of the p-values. Consensus Pathways. A. 
Sarcoidosis DEGs in lung and Lymph nodes.  B. DEG in TB (green), Sarcoidosis lymph node (blue), 
Sarcoidosis  lung (yellow) Cocci (black). 
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Sarcoidosis response was characterized by a predominant leucocyte activation and cell 
chemotaxis, TB response indicated a marked Interferon gamma-mediated response with 
collagen and extracellular matrix involvement, Cocci response was minor compared to 
other diseases at the pathway level, (<5 -log10 p value).  
 
5.  CURRENT GENETIC AND EPIGENETIC STRATEGIES IN SARCOIDOSIS 
PHENOTYPING   
 
5.1 Genome-wide DNA Methylation studies 
 
DNA methylation is one of the most important mechanisms involved in gene  and 
microRNA expression regulation. In this study, the candidate aimed to explore the potential 
role of DNA methylation in the heterogeneous clinical spectrum of sarcoidosis. Despite 
most sarcoidosis, patients enter remission, complicated sarcoidosis with progressive lung 
fibrotic disease occurs in 20% of the cases. Complications of fibrosis pulmonary include 
pulmonary hypertension from capillary obliteration. Lung transplantation is the last 
resource in these cases which carries and high mortality.  What triggers the evolution from 
contained granulomatous inflammation to pulmonary fibrosis is still unknown. Identifying 
epigenetic variants associated to DNA methylation that modulates the gene expression of 
genes that contribute to complicated sarcoidosis is relevant to predict complicate 
sarcoidosis clinical course. Cytosine methylation in CpG dinucleotides is an important 
mechanism involved in the regulation of multiple biological processes and pathological 
status.   
Using the microarray-based array by Illumina we assessed the methylation profile of 
47 sarcoidosis patients, 25 of them with progressive pulmonary involvement defined as 
pulmonary fibrosis (radiographic scadding staging IV or Ct scan) and 20 with self-limited 
pulmonary sarcoidosis(radiographic stages 0-IIor CT scan).  DNA was extracted from 
PBMCs using standard methods, followed by Illumina EPIC methylation 850K array CHIP. 
The BeadChip are mapped to gene regions based on their functional genome distribution 
and CpG island regions based on CpG content. We then calculated the Beta values, the 
ratio of the methylated probe intensity (sum of the methylated and methylated probe 
intensities), values were normalized and adjusted using combat. Then we compared the 
methylation between sarcoidosis with progressive lung fibrosis and the ones with the non 
complicated sarcoidosis (Figure 7). 
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Figure 8. MSD plot.  Methylated Site Display (MSD) in 27 complicated sarcoidosis defined as 
pulmonary fibrosis (radiographic stage IV)(Red) and 20  non complicated sarcoidosis.  
 
  
 
 
 
Our results indicate complicated sarcoidosis presents an important reduction in methylation 
in HLA associated genes; HLA-DRB1, HLA-DQA1, HLA-DRB6, HLA-DPA1, and KLRC4-
KLRK1 (β <0.18) and increased methylation in these genes; RADIL, DPPA3, MYT1L, HLA-
DRB1, and PAQR4 (β > 0.12).  Overrepresentation analysis indicated that the most 
significant pathways dysregulated associated to the hypo-methylated genes were MHC 
class II antigen presentation, Phosphorylation of CD3 and TCR, PD-1 signaling and TCR 
signaling. 
 
 
5.2 MiRNA Studies 
 
Subsequently, our research group explored MiRNA epigenetic regulatory mechanism in 
sarcoidosis. This study was published in Scientific Reports. Zhou T, Casanova N, Pouladi N, 
Wang T, Lussier Y, Knox KS, Garcia JGN. Identification of Jak-STAT signaling involvement in 
sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene 
signature. Sci Rep. 2017 Jun 26;7(1):4237. 
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 In this study, we paired the  MiRNA regulation and the utility of a protein-coding gene to 
identify an expression signature in sarcoidosis. We initially identified a 8-miRNA signature (7 
upregulated and 1 downregulated miRNAs in complicated sarcoidosis) that potentially relate to 
sarcoidosis severity, including miR-23a, miR-23b, miR-30c, miR-185, and miR-223, now 
recognized to be related to pulmonary hypertension(128-132) and lung cancer(133-136). To 
determine the differentially expressed protein-coding genes in sarcoidosis PBMCs, we 
analyzed the gene expression pattern from 35 healthy controls, 17 patients with uncomplicated 
sarcoidosis, and 22 patients with complicated sarcoidosis (Gene Expression Omnibus [GEO]12 
accession: GSE37912).  Spearman’s rank correlation test was conducted between gene 
expression and sarcoidosis severity. In total, 1,559 genes showed significant correlation 
(adjusted P < 0.0005), among which 340 genes showed positive correlation between gene 
expression and severity while the expression of 1,219 genes was negatively correlated with 
severity. Then we identified the 17-gene signature, in which the genes were potentially 
regulated by a 8-miRNA signature. We next searched the enriched Gene Ontology (GO) 
biological process terms (137) for the 17-gene signature and found that the 17-gene signature 
is significantly associated with “JAK-STAT cascade”. In agreement with prior reported studies, 
the 17-gene signature was enriched in Jak-STAT signaling pathway (126, 138, 139). Jak-STAT 
signaling pathway is an intracellular cascade initiated in response to cytokine signaling. 
Several genes in Jak-STAT pathway have already been associated with sarcoidosis, such as 
IL15 (140), IL23R (141), and STAT1 (142)derived a molecular signature consisting of 17 
protein-coding genes, which are potentially regulated by deregulated miRNA in sarcoidosis 
(Figure 9). 
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Figure 9. The pathway analysis of the MIRPSS 17 protein-coding gene revealed by Jak-Stat signaling pathway.  Panel A. 
The 17 protein-coding genes were differentially expressed with the severity of sarcoidosis. Y-axis indicates the gene expression 
level. HC: healthy controls; US: uncomplicated sarcoidosis; CS: complicated sarcoidosis.  Panel B. The top five GO biological 
process terms associated with the 17-gene signature. Panel C. The top five KEGG pathway terms associated with the 17-gene 
signature. The P-values were calculated by Fisher’s exact test. The dash line denotes the significance level of 0.05.  
 
Despite multiple efforts to identify concordant DE-miRNA in sarcoidosis, it is 
recognized that patterns of miRNA expression differ between BAL cells, lung tissue, lymph 
nodes and PBMCs suggesting organ specific regulation.  
We assigned a severity score (Sgene) to each patient based on the expression of the 
17-gene signature, which is a linear combination of the protein-coding gene expression 
values weighted by direction of differential expression (see Methods for details). Patients 
with more severe sarcoidosis are expected to have a higher Sgene. Not surprisingly, we 
found a significant positive correlation (Spearman’s rank correlation test: ρ = 0.615 and  P 
= 5.6×10-9).   We next validated the predictive power of the 17-gene signature in two 
independent blood gene expression datasets. One dataset (GEO accession: GSE19314) 
(126) is from University of California, San Francisco that contains 20 healthy controls and 
40 sarcoidosis patients (UCSF cohort). The other dataset (GEO accession: GSE18781) 
(142) is from Oregon Health Sciences University and includes 25 healthy controls and 12 
sarcoidosis patients.  
 In agreement with prior reported studies, the 17-gene signature was enriched in 
Jak-STAT signaling pathway (126, 138, 139) . In our 17-gene signature, CBLB and IL6ST 
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are known to be involved in T-cell receptor signaling and cytokine-cytokine receptor 
interaction, respectively, according to the definition in KEGG database. However, we failed 
to identify a single gene within our 17-gene signature that overlapped with the previously 
published sarcoidosis blood gene signatures by Koth et al (126) and Zhou et al (138), 
respectively. 
In summary, we derived a molecular signature consisting of 17 protein-coding 
genes, which are potentially regulated by deregulated miRNA in sarcoidosis. This 
signature can be independently used as potential novel molecular markers for 
differentiating patients with sarcoidosis, especially for distinguishing the patients with risk 
of complicated sarcoidosis. 
 
5.3 GWAS-eQTL Polymorphism Studies with Massarray Validation 
Genome-wide association studies (GWAS) require large sample size to have 
enough power. Furthermore, the majority of SNPs detected are in noncoding regions 
complicating the understanding of the role that such variant play in the disease 
mechanism. New approaches to increase the power of GWAS involve the integration of 
expression quantitative loci (eQTL) studies, a powerful method to identify regions of the 
genome that co-segregate with a given trait. 
In this work, the candidate and her research team took advantage of multiple 
catalogs of eQTLdata, and regulatory annotations to identify SNPs that co-localize with the 
genetic information from GWAS Sarcoidosis studies performed by the Garcia Lab in EA 
and AA populations. Our analysis, enriched for 60 intragenic and 190 intergenic coding 
SNPs that colocalize with previously identified eQTLs, ten of them with lung eQTLs and 
eleven have whole blood eQTLs. 175 SNPs had significant FDR values for cis westra 
eQTLs (<1E-03).  We identified SNPs with eQTLs for genes associated to JAK/STAT 
pathway STAT1, IL12B and PSMC1, a pathway we previously reported involved in 
complicated Sarcoidosis. Furthermore, we identified two specific variants in complicated 
sarcoidosis related to lung fibrosis pathway, rs8124478 and rs2546893.  (rs7300241and 
rs758167) from the same gene associated to complicated sarcoidosis in both AA and EA.  
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 Table 7. Top intersected SNPS with eQTLs by race and complicated status and top 
signaling pathways. 
 
 
Next, we conducted a validation utilizing MassARRAY, a DNA analysis platform that uses 
mass spectrometry to measure the amount of genetic target material and/or variations. A 
total of 976 DNA samples were included, 336 and 625 African American and whites. Data 
was generated for 103 of 113 SNPs, with 54 SNPs called over 99.5% success rate. Our 
results validated 13 polymorphisms associated to risk and severity in sarcoidosis in AA, EA 
and one SNP, rs7219 associated to risk for complicated sarcoidosis in EA. Table 7. 
eQTL Chr p-val eQTL-pval Gene symbols Tissues Pathway function
rs502771 6 1.27E-04 1.52E-10
C4A; C4B; CLIC1; CYP21A1P; CYP21A2; HLA-DMA; HLA-DQA1; 
HLA-DQB1; HLA-DQB1-AS1; HLA-DQB2; HLA-DRB1; HLA-DRB5; 
HLA-DRB9; NOTCH4; PSMB9 Lung, Heart, Brain & Blood Immunological
rs7746922 6 4.29E-04 2.15E-10
C2; C4A; C4B; CYP21A1P; HLA-DMA; HLA-DQA1; HLA-DRB5; 
MICB; NOTCH4; PSMB9; RNF5 Lung, Heart, Brain & Blood Immunological 
rs17787966 11 5.83E-05 2.10E-08
ACP2; ARHGAP1; C11orf49; C1QTNF4; DDB2; LRP4; LRP4-AS1; 
PACSIN3 Lung, Heart & Blood Vesicle-mediated transport
rs3094228 6 1.71E-05 3.35E-10
C4A; C4B; CCHCR1; CYP21A1P; CYP21A2; HCG22; HLA-C; MICB; 
NOTCH4; PPP1R18; PSORS1C1; VARS2 Lung, Heart, Brain & Blood Immunological
rs9268362 6 1.38E-04 7.99E-11 FKBPL; HLA-DQA2; HLA-DRB1; HLA-DRB6; NOTCH4 Lung, Heart, Brain & Blood Immunological 
rs2844627 6 6.31E-05 3.31E-12
C4A; C4B; C6orf15; CCHCR1; CYP21A1P; HCG20; HCG22; HLA-
B; HLA-C; MICB; NOTCH4; POU5F1; PPP1R18; PSORS1C2; 
RNF5; VARS2; WASF5P Heart, Brain & Blood Immunological
rs7787110 7 9.37E-04 2.08E-68 AK3P3; GPNMB; KLHL7; KLHL7-AS1; NUPL2 Lung, Heart, Brain & Blood Biological oxidations
rs10903129 1 8.29E-04 4.62E-21 RHCE; RHD; SDHDP6; TMEM50A; TMEM57 Lung, Heart, Brain & Blood Biological oxidations
rs113413 22 9.24E-04 9.80E-62 DDT; DDTL; GSTT2; GSTT2B; MIF; MIF-AS1 Lung, Heart, Brain & Blood Biological oxidations
rs9889755 17 4.86E-05 1.27E-27 ATAD5; CRLF3; LRRC37BP1; SUZ12P1; TEFM Lung, Heart, Brain & Blood Lymphocyte activation
rs1052053 1 2.23E-04 1.52E-11 GLMP; PAQR6; SEMA4A; SLC25A44; SMG5 Lung & Blood Lymphocyte activation
rs11912715 22 2.26E-04 1.52E-20 MMP11; SLC2A11; SMARCB1; VPREB3 Lung, Heart, Brain & Blood Immunoglobulin production
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Additionally we compiled literature published SNPs consisting in 15 SNPs and 16 genes, 
GWAS catalog 41 SNPs and 45 Genes and included our variants validated Massarray 
SNPs. We annotated SNPs and map them to specific regions in the genome; our results 
identified a proportionally high number of genes in chromosome 6p21.Figure 10. 
 
 
 
Table 8. GWAS eQTL variants validated associated to sarcoidosis susceptibility and severity. 
SNP  Group risk association Genes Affected 
rs7248735  AA   IL27RA 
rs10044736  AA   CTNNA1 SIL1 
rs11677881  AA   DDX11L2 FAM138B PGM5P4 PGM5P4-AS1 RABL2A RPL23AP7 WASH2P 
rs1476792  AA   PTPRCAP 
rs17787966  AA   ACP2 ARHGAP1 C11orf49 C1QTNF4 DDB2 LRP4 LRP4-AS1 PACSIN3 
rs2054517  AA   GLIPR1 GLIPR1L2 KRR1 
rs2596509  AA   ATP6V1G2 CCHCR1 HLA-B HLA-S MICA PSORS1C1 PSORS1C2 STK19B VARS2 ZBTB12 
rs443532  AA   PIK3R5 
rs502771  AA   
C4A C4B CLIC1 CYP21A1P CYP21A2 HLA-DMA HLA-DQA1 HLA-
DQB1 HLA-DQB1-AS1 HLA-DQB2 HLA-DRB1 HLA-DRB5 HLA-
DRB9 NOTCH4 PSMB9 
rs6779819 EA C3orf18 DOCK3 HEMK1 LINC02019 MAPKAPK3 TEX264 
rs1442533 EA CNTLN 
rs7549445 EA JAK1 RP11-182I10.3 
rs7219  EA Complicated NUP85 MRPS7 GRB2 
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Figure 10. Genomic location of SNPs associated with sarcoidosis.  
 
We confirmed several SNPs associated with complicated sarcoidosis majority 
associated to immunological pathways associated to HLA complex-genes.  By integrating 
functional datasets and eQTLs we can prioritize the results and identify risk associated 
SNPs that predict complicated sarcoidosis. 
 
6. MATERIALS AND METHODS 
   Human Subjects' Protections and Risk.   All study personnel was certified in 
the ethical conduct of human biomedical, genetics research, and HIPPA information 
security. Data recorded and collected by the investigators at the clinical centers was coded 
and given a unique ID code. This information along with consents will remain in a locked 
filing cabinet within the Principal Investigator’s office. Data was stored in computer files 
within a locked office and will require a password to access via an encrypted, password-
protected web based RedCap system at University of Arizona. Training of clinical center 
staff occurred  prior to the enrollment of the first patient. Since the system is expected to 
be completed online, an electronic copy of the website submission will be available at the 
end of the encounter and will serve as the source document kept at the clinical site. 
Source documents were saved electronically according to Good Clinical Practice. All 
genomic data was be behind a University of Arizona firewall and protected as required to 
minimize risk of breach of confidentiality present in all genetic/genomic studies.  We also 
included the use of codes to identify subjects and securing all genetic samples and clinical 
data at locked sites and genomic data will be stored in secure servers.  
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De identified samples from about 1200 sarcoidosis patients from the Garcia 
laboratory’s biorepository, all met ERS/ATS criteria for a diagnosis of sarcoidosis, were 
available for this research. Samples were part of the biorepository from Dr. Garcia, 
obtained from material transfer agreements and additional recruiting studies IRB approved 
# 1312168664 and1312166668. Sarcoidosis phenotypic data included clinical data to 
evaluate the organ involvement among complicated and uncomplicated cases.  Groups 
were stratified in complicated and uncomplicated categories based on organ involvement 
type and acute and not acute presentation and number of organs affected. Complicated 
sarcoidosis defined as Lung involvement with parenchymal lung disease confirmed by CT 
scan, X-R Scadding stages III and IV and/or PFT with FVC <50%.  Organ involvement: 
Cardiac or neurological involvement in addition to the lungs. In addition, clinical Course 
(remitting, chronic, and uncertain) was determined. 
 
Ex vivo Genome-wide gene expression in PBMC 
The experiment consisted of stimulation of peripheral blood mononuclear cells 
(PBMC)with TNF-α (20ng/ul for 6 hours). RNA from stimulated and unstimulated PBMCs 
was extracted following Qiagen’s miRNA easy protocol.SMARTer Stranded Total RNA-seq 
kit-Pico was used for cDNA library preparation. Samples were sequenced  using High-
throughput  RNA  sequencing (RNA-seq) on  Illumina  HiSeq  3000 instrument. For this 
pilot study, four sarcoidosis patients (two complicated  and two on-complicated  cases)  
with three  replicas  from  each  one  were submitted  to  RNAseq.   Fastq files were  
aligned  using the HISAT software. The transcripts were reconstructed and quantified 
using the StirngTie software and  the latest version  of  the  GTF annotations  from  
ensemble  (GRCh38.87). The differential expression analysis (DEA) was performed 
independently by using two programs Ballgown and cuffdiff. We consider a genes to be 
dysregulated if the p-values of the DEA was < 0.0001.  The differentially expressed genes 
(DEGs) were submitted to gene enrichment using the integrative interaction network server 
“ConsensusPathDB-human” provided by the Max Planck Institute for Molecular Genetics, it 
provides access to most of the available pathway databases on a single site. 
 
Gene Expression in Granulomatous Tissue 
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We analyzed gene expression profiles of microdisected granulomatous tissue from 
30 subjects and 6 healthy individuals. Tissue specimens were collected  from clinically 
indicated biopsies for diagnosis purposes. De-identified specimens were obtained from the 
Tissue Acquisition Shared Resource at the University of Arizona and approved by the 
Human subjects Protection Program IRB # 1509097312A001. Formalin fixed paraffin-
embedded (FFPE) microdissections from lung and lymph node granulomatous tissue from 
Healthy (6) Sarcoidosis (22), Coccidioidomycosis (4) and Tuberculosis (4) assayed using 
Next Generation Sequencing-based gene expression by HTG EdgeSeq Oncology-
biomarker panel assay (HTG Molecular Diagnostics, Inc.).  The panel conveyed 2558 
probes, 15 housekeeper genes, four negative process controls and four positive process 
controls for quantitative analysis of targeted mRNAs.  Multiple genes part of pathways 
previously identified as relevant in sarcoidosis such as the interferon, MAP kinase, NFКB, 
the JAK/STAT (46, 126, 138) and other immune-oncologic related pathways were covered 
by this panel (143). 
Gene expression profiling platform.  Representative tissue sections from 
granulomatous tissue were hematoxylin and eosin- stained. Microdissection areas were 
selected by an expert pathologist, approximately 1.5 mm² of a 5μm tick FFPE tissue section 
from granulomas were microdissected, about 5-10 sections per subject were lysed and 
followed by and RNA extraction-free chemistry method using the HTG®’s assay kit. Next, 
for library preparation the HTG Edge processor for nuclease protection steps was used, 
followed by PCR tagging, library amplification, quantitation and normalization. Sequencing 
was performed on an Illumina MiSeq using 150-cycle V3 kits.  Expression data was 
generated using FASTQ files. For the bioinformatic analysis, we generated the 
transcriptome index using the salmon package (144) and a fasta file containing the 
sequence of the HTG EdgeSeq 2567 probes. Quantification was performed  for each sample 
using the salmon quant command(144), using the index file and the corresponding fastq file. 
The raw counts were loaded into R using the tximport package(145).  The Differential 
Expression (DE) was calculated using Limma. Functional analysis. A list with statistically 
significant genes for each comparison was submitted to the human ConsensusPathDB (146) 
website using the over representation gene set analysis against the pathway databases and 
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the gene ontology categories using a minimum overlap with input list of 2 and a p-value 
cutoff of 0.01. 
GWAS-eQTL Polymorphism Studies with Massarray Validation 
We analyzed the genetic risk predisposing to complicated sarcoidosis in African 
Americans (AA), European Americans and healthy controls from the Genetic Association 
Information Network (GAIN) (627 AA and 579 EA). Prioritized SNPs on each category were 
annotated and intersected with eQTLdata sets from GTEx 7.0. Massarray validation. For 
SNP Genotyping validation we utilized the MassARRAY®system, which uses the 
iPLEX®assay with primer extension chemistry to allow efficient multiplexing of upwards of 
30SNPs. PCR products are crystallized on the matrix surface of the SpectroCHIP®. A total 
of 976 DNA samples were included for MassARRAY, 336 and 625 African American and 
whites respectively, about 30% of them were classified as complicated sarcoidosis.   Data 
was generated for 103 of 113 SNPs, with 54 SNPs called over 99.5% success rate. 
DNA methylation.  
Genomic DNA was extracted from PBMC collected at subject enrollment.  Using the 
Illumina 850K EPIC array, the DNA was hybridized to the EPIC BeadChip using Zymo 
Bisulfite Conversion for DNA methylation. DNA methylation assays were performed at the 
Genomics and Microarray Core at the University of Colorado Denver.  Briefly, DNA (250–
750 ng) was treated with sodium bisulphite using the EZ DNA methylation kit (Zymo 
Research, CA, USA). DNA methylation was quantified using the Illumina Infinium and 
HumanMethylationEPIC (EPIC) BeadChip (Illumina, CA, USA). Raw IDAT files were 
processed with Illumina’s GenomeStudio software V2011.1 and background normalized 
using negative control probes to generate methylation β-values which were used for all 
downstream analyses. All analyses were conducted in R statistical software. Limma 
Bioconductor package was used to parse data and to perform differential methylation 
analysis.  In total, we included 47 sarcoidosis patients, 25 of them with progressive 
pulmonary involvement defined as pulmonary fibrosis (radiographic scadding staging IV or 
CT scan) and 20 with self-limited pulmonary sarcoidosis (radiographic stages 0-IIor CT 
scan).  We removed any technically unreliable probes. We calculated methylation levels 
from raw data using B values. 
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7. DISCUSSION AND CONCLUSION 
Conventional biomarkers have been be insufficiently sensitive for implementation in 
routine clinical care.  In my dissertation, I focused on the utilization utilizing genomic base 
approaches based on high-throughput molecular assays to characterize genotype, gene 
expression, and epigenetics that define sarcoidosis subphenotypes.  
Our results demonstrated that the integration of eQTL data from GTex studies 
increase the power of underpowered GWAS studies. This innovative method allowed the 
identification of SNPs associated to complicated sarcoidosis in AA and in EA, and 
then we validated some of these SNPs by Massarray. Following a Masarray validation, we 
replicated associations for several previously reported sarcoidosis-susceptibility risk loci in 
our AA collection, including MHC Class II region genes. It is known that the MHC Class II 
region plays a major role in immune-mediated disorders, including associations to celiac 
disease, insulin-dependent diabetes mellitus, rheumatoid arthritis, multiple sclerosis, and 
systemic lupus erythematosus.  
Our analysis also replicated associations HLA-DRA, HLA-DRB5, HLA-DRB1, 
BTNL2, and ANXA11 in both our AA and EA datasets.  Similarly, BTNL2, and ANXA11 
have been suggested to play a role in T-cell activation (100, 147). Following MAsrray 
validation confirmed sarcoidosis association with two HLA related SNPS, rs2596509 (HLA-
B, PSORS1C1) and rs502771 (HLA-DQB1, HLA DQA1); other non-HLA related variants 
were also validated, among them rs72248735 (RLN3/ IL2RA). NOTCH4 gene, previously 
identified as sarcoidosis-associated locus in AA (32), reached genome-wide significance in 
our AA samples (rs715299). We identified significant association between sarcoidosis and 
a previously underreported locus (JAK1) in our EA cohort, JAK1 is a membrane protein 
member of a class of protein-tyrosine kinases (PTK) that phosphorylates STAT proteins 
(signal transducers and activators of transcription) and plays a key role in interferon-
alpha/beta and interferon-gamma signal transduction. JAK/STAT pathway was reported as 
dysregulated in our first miRNA epigenetic study (148). In this study, we identified 46 
microRNAs and 1,559 genes that were differentially expressed across sarcoidosis and 19 
microRNA-mRNA regulatory pairs that derived a 17  unique  protein-coding gene  
signature whose  pathway  analysis revealed  JAK/STAT  signaling  pathway  as  the  most 
significantly  represented  pathway.  A severity score based  on  the expression  of  the  
17-gene  signature showed an  increasing  trend  in complicated sarcoidosis useful in 
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diagnosis  and severity assessment of sarcoidosis. Additional relevant epigenetics 
correlations with methylation data were identified in the GWA eQTL variants. For 
example, HLA-DRB1 had a reduction of 50% methylation in complicated sarcoidosis; 
similarly, HLA-DR QA1 observed a reduction of 31% of methylation in complicated cases. 
The integration of epigenetics to the genomic variants corroborates the presence of 
specific regions in the genome relevant for risk and severity of sarcoidosis.   
The PBMCs transcriptomic responses to TNF-α exposure in complicated and 
uncomplicated sarcoidosis was analyzed.  We identified the presence of a differential 
dysregulation in genes associated to metabolic pathways. As expected, immune system (p 
value1.77e-12 for 80 genes) and Cytokine-cytokine receptor interaction (p-value of 8.2e09) 
were the top dysregulated pathways. Our analyses also showed a prominent MAPK 
activation and interferon response to TNF-α stimulation that was unique to those PBMCs 
drawn from complicated sarcoidosis patients. This mitogen-activated protein kinase 
(MAPK) cascade is a critical pathway described in human cancer cell survival, specifically 
involved in cellular proliferation (149). It allows for the periodic environmental adaptation 
necessary for activation and regulation for cell survival, events that are critical for the 
granuloma proliferation. We also showed for the first time, activation of interferon by 
PBMCs in response to TNF-α in complicated sarcoidosis. Our study therefore, not only 
provides transcriptional changes in PBMCs but also reveals a role for TNF-α signaling in 
sarcoidosis severity. We recognized that one of the limitations of this study is the limited 
number of patients included, four in total. Despite this limitation, this study highlights the 
capacity to differentiate response to the same cytokine at different clinical stages.  
We captured transcriptomic profile within the granulomas of sarcoidosis in the 
two most commonly affected compartments using next generation   sequencing   
expression   not   previously   reported   before. Results revealed   significant   divergence   
at   the   genomic   level between these compartments. Granulomas from lymph node and 
lung had 10 only overlapping dysregulated genes; ADAMTS1, CXCL2, HSPB6, ITGA9, 
NPR1, NR4A1, CCL14, CXCL9, FABP4 and NR1H3, while only the six first genes were 
exclusively dysregulated in sarcoidosis (not in Tb or cocci). These hub genes ADAMST1, 
CXCL2, CXCL9, and FABP4 were validated in independent microarray sets.  At the 
pathway level, transcriptome derived from lymph nodes delineated a clear immunological 
response, involving leucocyte migration and neutrophil chemotaxis; while a structural 
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regenerative response was observed at the lung level characterized by cell migration and 
angiogenesis. These later changes associated to a progressive  lung involvement that 
follows the initial hilar lymphadenopathy involvement.   Additionally, we compared the 
genomic profile of granulomas in Sarcoidosis vs TB and Cocci. This study 
corroborated that some genes previously suggested as potential sarcoidosis markers were  
also  present  in  fungal  or  mycobacterium  granulomas. For example,  we identified  that 
CXCL9,  a  chemoattractant  for  lymphocytes,  previously  proposed  as  a marker of 
severity in sarcoidosis (26)is also over-expressed in TB. Previous microarray studies 
identified that CXCL9 is also dysregulated in Beryllium disease (27), another 
granulomatous disease.  Similarly, we identifiedaNOTCH4 downregulation in our panel in 
lung sarcoidosis (p value 0.0008). NOTCH4 was previously  reported  as  a  sarcoidosis-
associated locus in genome-wide associated study in African Americans (1), its signaling is  
initiated  after  activation  of  toll-like  receptor  in  macrophages. CXCL13,  another 
chemokine promotor of B cell migration by regulation of Ca influx, it was previously 
proposed as a biomarker for uveitis (28, 29), a condition affecting one third of sarcoidosis 
patients even before the systemic disease is manifested (30). We identified that CXCL13, 
CD27 and SLAMF7, were the only transcripts dysregulated in Cocci, TB and sarcoidosis 
(lymph nodes). CXCL13 is a chemokine with key role in B cell migration (24), while 
SLAMF7 is a regulator of T lymphocyte development and function such as lytic activity and 
a modulator of B cell activation and memory (25). Furthermore, CD27 regulates B-cell 
activation and immunoglobulin synthesis through to the activation of NF-kappa B and 
MAPK8/JNK. This   finding, points to a diverse   molecular   mechanism present   in 
granulomatous diseases that result in a similar histopathological finding.   Three of  the 
downregulated genes,  SERTAD1,    HBEGF  and  KLRB1,  profiled  by  this oncopanel, 
were also previously identified as part of our 20gene signature generated by microarray in  
peripheral  blood  from  PBMCs(26). However,  we  found  that KLRB1, however, is not  
exclusively downregulated in  sarcoidosis,  but  also  present  in  TB. Similarly, SERTAD1 
was also significantly downregulated in Cocci. Another  gene  part  of  the  same  gene  
signature  was  the  Heparin-binding  epidermal  growth  factor (HBEGF), involved in 
epithelialization, wound contraction and angiogenesis. It also has a pro-inflammatory  role  
in  skin  and  lung  lesions  such  as  alveolar regeneration  after pneumectomies  (24),  
pneumonitis  and  commonly  found  in  early  stages  of  systemic sclerosis (25).We 
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confirmed that HBEGF was down-regulated in granulomas from lung (FC-2.36  p0.0016)  
exclusively  in  sarcoidosis. Furthermore, our research group previously conducted 
epigenetic studies in sarcoidosis identifying IL6STand STAB1as part of a MiRNA-derived 
gene signature for complicated sarcoidosis (5). This time we identified that IL6STwas 
significantly dysregulated only in TB granuloma(FC -1.42 and p 0.0008),  whileSTAB1  
gene  was  significantly  downregulated  in  lymph  nodes  in sarcoidosis  (FC -1.64  p  
0.0014).  STAB1 codes for a transmembrane receptor that is expressed in endothelial cells 
and lymph nodes, with functions in angiogenesis, lymphocyte homing and cell adhesion. 
ADMATS1 seems to be an important regulator of the pathogenic mechanism associated to 
the granuloma formation in sarcoidosis. Initially identified as DEG by this oncopanel as 
exclusively dysregulated  in  both  compartments,  then it  was validated  by  microarray 
analysis in  both  tissues in sarcoidosis.  This gene encodes a disinterring and 
metalloproteinase with thrombospondin motif associated with various inflammatory 
processes. Leveraging the power derived from multiple microarray data sets, were able to 
conduct a validation of the expression level of the DE panel-derived genes. We validated 
70 of the 241  DEG  derived  from  the  biomarker  panel  were  also  dysregulated  in  
independent cohorts of sarcoidosis, tuberculosis and valley fever.  Despite the selection of 
granuloma microdisected areas for oncopanel sequencing, we were able to detect that 
tissue origin imprints an effect at the expression level in both platforms.  Clinical 
implications Identifying  transcription  profiles  from  cells  histologically  derived  
microdissections  of granulomas, in diverse diseased tissue can help as a diagnostic tool 
to identify affected individuals and indicate genes, pathways and cells affected, improving 
the understanding of  enigmatic  diseases  like  sarcoidosis  and  enabling  the  design  of  
new  therapeutic interventions. This relevant translational information was derived from 
newly diagnosed and treatment naïve patients.  In summary, this study corroborated that 
some genes previously suggested as potential sarcoidosis markers were also present in 
fungal or mycobacterium granulomas pointing to a common mechanistic origin. We 
demonstrated that granulomas from sarcoidosis share stronger similarity at the 
transcriptional and pathway level with TB than with Cocci. 
In summary, the studies presented as part of this dissertation summarized the utility 
of the use of alternate strategies for biomarkers development utilizing genomic base 
approaches based on high-throughput molecular assays.  The candidate identified novel 
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variants associated to sarcoidosis sub-phenotypes, analyzed and compared the gene 
expression at the tissue level, and highlighted some of the epigenetics modifications 
associated to sarcoidosis subphenotypes. From the epigenetics analysis, she also 
identified dysregulated novel miRNAs associated to complicated sarcoidosis and altered 
methylation patterns in loci, HLA among others associated to sarcoidosis by GWAS. 
 
 
 
 
 
REFERENCES 
 
1. R. P. Baughman, M. Iannuzzi, Tumour necrosis factor in sarcoidosis and its potential for 
targeted therapy. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 
17, 425-431 (2003). 
2. E. Hem, [Multiple benign sarcoid of the skin--100 years since Caesar Boeck's pioneering 
article]. Tidsskr Nor Laegeforen 119, 4567-4569 (1999). 
3. P. Spagnolo, Sarcoidosis: a Critical Review of History and Milestones. Clin Rev Allergy Immunol 
49, 1-5 (2015). 
4. Y. Ma, A. Gal, M. N. Koss, The pathology of pulmonary sarcoidosis: update. Semin Diagn 
Pathol 24, 150-161 (2007). 
5. K. K. Shah, B. S. Pritt, M. P. Alexander, Histopathologic review of granulomatous inflammation. 
J Clin Tuberc Other Mycobact Dis 7, 1-12 (2017). 
6. Y. Rosen, Pathology of sarcoidosis. Semin Respir Crit Care Med 28, 36-52 (2007). 
7. S. Saidha, E. S. Sotirchos, C. Eckstein, Etiology of sarcoidosis: does infection play a role? Yale 
J Biol Med 85, 133-141 (2012). 
8. I. Kroes, P. W. Lepp, D. A. Relman, Bacterial diversity within the human subgingival crevice. 
Proceedings of the National Academy of Sciences of the United States of America 96, 14547-
14552 (1999). 
9. B. J. Paster et al., Bacterial diversity in human subgingival plaque. J Bacteriol 183, 3770-3783 
(2001). 
10. Z. Gao, C. H. Tseng, Z. Pei, M. J. Blaser, Molecular analysis of human forearm superficial skin 
bacterial biota. Proceedings of the National Academy of Sciences of the United States of 
America 104, 2927-2932 (2007). 
11. E. M. Bik et al., Molecular analysis of the bacterial microbiota in the human stomach. 
Proceedings of the National Academy of Sciences of the United States of America 103, 732-737 
(2006). 
12. S. R. Gill et al., Metagenomic analysis of the human distal gut microbiome. Science 312, 1355-
1359 (2006). 
13. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the 
European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other 
Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS 
Executive Committee, February 1999. Am J Respir Crit Care Med 160, 736-755 (1999). 
14. W. P. Drake et al., Cellular recognition of Mycobacterium tuberculosis ESAT-6 and KatG 
peptides in systemic sarcoidosis. Infect Immun 75, 527-530 (2007). 
   
56 
 
15. Z. Song et al., Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive 
immune response in systemic sarcoidosis. J Exp Med 201, 755-767 (2005). 
16. Y. Eishi et al., Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes 
of Japanese and European patients with sarcoidosis. J Clin Microbiol 40, 198-204 (2002). 
17. K. Yamamoto et al., Catalase expression of Propionibacterium acnes may contribute to 
intracellular persistence of the bacterium in sinus macrophages of lymph nodes affected by 
sarcoidosis. Immunol Res 67, 182-193 (2019). 
18. Y. Ebe et al., Proliferative response of peripheral blood mononuclear cells and levels of antibody 
to recombinant protein from Propionibacterium acnes DNA expression library in Japanese 
patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 17, 256-265 (2000). 
19. I. Ishige et al., Propionibacterium acnes is the most common bacterium commensal in 
peripheral lung tissue and mediastinal lymph nodes from subjects without sarcoidosis. 
Sarcoidosis Vasc Diffuse Lung Dis 22, 33-42 (2005). 
20. C. M. Swaisgood et al., Development of a sarcoidosis murine lung granuloma model using 
Mycobacterium superoxide dismutase A peptide. Am J Respir Cell Mol Biol 44, 166-174. 
21. J. Minami et al., Pulmonary granulomas caused experimentally in mice by a recombinant 
trigger-factor protein of Propionibacterium acnes. J Med Dent Sci 50, 265-274 (2003). 
22. D. R. Moller et al., Rationale and Design of the Genomic Research in Alpha-1 Antitrypsin 
Deficiency and Sarcoidosis (GRADS) Study. Sarcoidosis Protocol. Ann Am Thorac Soc 12, 
1561-1571 (2015). 
23. K. A. Oswald-Richter et al., Cellular responses to mycobacterial antigens are present in 
bronchoalveolar lavage fluid used in the diagnosis of sarcoidosis. Infect Immun 77, 3740-3748 
(2009). 
24. K. A. Oswald-Richter et al., Multiple mycobacterial antigens are targets of the adaptive immune 
response in pulmonary sarcoidosis. Respir Res 11, 161. 
25. E. Chen, e. al, Serum Amyloid A Regulates Granulomatous Inflammation in Sarcoidosis through 
Toll-like Receptor-2. Am J Respir Crit Care Med 181, 360-373 (2010). 
26. E. Chen, D. R. Moller, Sarcoidosis—Scientific Progress and Clinical Challenges. Nat Rev 
Rheumatol 7, 457-467 (2011). 
27. S. T. Brown et al., Recovery of cell wall-deficient organisms from blood does not distinguish 
between patients with sarcoidosis and control subjects. Chest 123, 413-417 (2003). 
28. E. Jonsson, B. Jarvholm, M. Andersson, Silica dust and sarcoidosis in Swedish construction 
workers. Occup Med (Lond),  (2019). 
29. L. E. Crowley et al., "Sarcoid like" granulomatous pulmonary disease in World Trade Center 
disaster responders. Am J Ind Med 54, 175-184 (2011). 
30. G. Izbicki et al., World Trade Center "sarcoid-like" granulomatous pulmonary disease in New 
York City Fire Department rescue workers. Chest 131, 1414-1423 (2007). 
31. M. Ramos-Casals, B. Kostov, P. Brito-Zeron, A. Siso-Almirall, R. P. Baughman, How the 
Frequency and Phenotype of Sarcoidosis is Driven by Environmental Determinants. Lung 197, 
427-436 (2019). 
32. I. Adrianto et al., Genome-wide association study of African and European Americans implicates 
multiple shared and ethnic specific loci in sarcoidosis susceptibility. PLoS One 7, e43907 
(2012). 
33. T. E. Fingerlin, N. Hamzeh, L. A. Maier, Genetics of Sarcoidosis. Clin Chest Med 36, 569-584 
(2015). 
34. A. Fischer et al., Genetics of sarcoidosis. Semin Respir Crit Care Med 35, 296-306 (2014). 
35. M. C. Iannuzzi, B. A. Rybicki, Genetics of sarcoidosis: candidate genes and genome scans. 
Proc Am Thorac Soc 4, 108-116 (2007). 
36. B. A. Rybicki et al., Familial aggregation of sarcoidosis. A case-control etiologic study of 
sarcoidosis (ACCESS). Am J Respir Crit Care Med 164, 2085-2091 (2001). 
   
57 
 
37. P. Brito-Zeron, B. Kostov, D. Superville, R. P. Baughman, M. Ramos-Casals, 
Geoepidemiological big data approach to sarcoidosis: geographical and ethnic determinants. 
Clin Exp Rheumatol,  (2019). 
38. M. H. Tukey et al., Mortality among African American women with sarcoidosis: data from the 
Black Women's Health Study. Sarcoidosis Vasc Diffuse Lung Dis 30, 128-133 (2013). 
39. M. C. Iannuzzi, B. A. Rybicki, A. S. Teirstein, Sarcoidosis. N Engl J Med 357, 2153-2165 (2007). 
40. H. Nunes, D. Bouvry, P. Soler, D. Valeyre, Sarcoidosis. Orphanet J Rare Dis 2, 46 (2007). 
41. N. Soto-Gomez, J. I. Peters, A. M. Nambiar, Diagnosis and Management of Sarcoidosis. Am 
Fam Physician 93, 840-848 (2016). 
42. M. H. Noe, M. Rosenbach, Cutaneous sarcoidosis. Curr Opin Pulm Med 23, 482-486 (2017). 
43. R. P. Baughman et al., Defining the clinical outcome status (COS) in sarcoidosis: results of 
WASOG Task Force. Sarcoidosis Vasc Diffuse Lung Dis 28, 56-64 (2011). 
44. M. C. Iannuzzi, J. R. Fontana, Sarcoidosis: clinical presentation, immunopathogenesis, and 
therapeutics. JAMA 305, 391-399. 
45. G. C. Nancy, Z. Tong, N. Jorge, S. K. Kenneth, G. N. G. Joe, in A108. MICRO RNAS, RNA 
SEQ, LNCRNA: BIOLOGY AND FUNCTION. (American Thoracic Society, 2016), pp. A2809-
A2809. 
46. T. Zhou et al., U. o. N. University of Arizona, Ed. (Scientific Reports, 2017). 
47. R. P. Baughman, U. Costabel, R. M. du Bois, Treatment of sarcoidosis. Clin Chest Med 29, 533-
548, ix-x (2008). 
48. A. S. Morgenthau, M. C. Iannuzzi, Recent advances in sarcoidosis. Chest 139, 174-182. 
49. J. Harris, J. C. Hope, J. Keane, Tumor necrosis factor blockers influence macrophage 
responses to Mycobacterium tuberculosis. The Journal of infectious diseases 198, 1842-1850 
(2008). 
50. O. Y. Saliu, C. Sofer, D. S. Stein, S. K. Schwander, R. S. Wallis, Tumor-necrosis-factor 
blockers: differential effects on mycobacterial immunity. The Journal of infectious diseases 194, 
486-492 (2006). 
51. A. Mohan et al., Transcriptional survey of alveolar macrophages in a murine model of chronic 
granulomatous inflammation reveals common themes with human sarcoidosis. Am J Physiol 
Lung Cell Mol Physiol 314, L617-L625 (2018). 
52. I. S. Jacob Sellares, Elliot D. Crouser, Marina A. Freudenberg, Mridu Gulati,  Simon Hart, Erika 
Herzog, Martin Kolb, Thomas Weichhart, Wonder P. Drake, Ginger Spitzer, Noopur Singh, 
Daniel A. Culver New advances in the development of sarcoidosis models: a synopsis of a 
symposium sponsored by the Foundation for Sarcoidosis Research. SARCOIDOSIS 
VASCULITIS AND DIFFUSE LUNG DISEASES 35, 2-4 (2018). 
53. N. J. Sweiss et al., Rheumatologic manifestations of sarcoidosis. Semin Respir Crit Care Med 
31, 463-473 (2010). 
54. M. Drent, J. P. Cremers, T. L. Jansen, Pulmonology meets rheumatology in sarcoidosis: a 
review on the therapeutic approach. Curr Opin Rheumatol 26, 276-284 (2014). 
55. N. Casanova, T. Zhou, K. S. Knox, J. G. Garcia, Identifying Novel Biomarkers in Sarcoidosis 
Using Genome-Based Approaches. Clin Chest Med 36, 621-630 (2015). 
56. J. A. Bons et al., in Respir Med. (England, 2007), vol. 101, pp. 1687-1695. 
57. A. Rozy et al., Inflammatory markers in the exhaled breath condensate of patients with 
pulmonary sarcoidosis. J Physiol Pharmacol 57 Suppl 4, 335-340 (2006). 
58. H. Ahmadzai et al., Measurement of neopterin, TGF-beta(1) and ACE in the exhaled breath 
condensate of patients with sarcoidosis. Journal of Breath Research 7,  (2013). 
59. S. Gungor et al., Conventional markers in determination of activity of sarcoidosis. Int 
Immunopharmacol 25, 174-179 (2015). 
60. A. J. Tahmoush et al., CSF-ACE activity in probable CNS neurosarcoidosis. Sarcoidosis Vasc 
Diffuse Lung Dis 19, 191-197 (2002). 
   
58 
 
61. B. Beneteau-Burnat, B. Baudin, Angiotensin-converting enzyme: clinical applications and 
laboratory investigations on serum and other biological fluids. Critical reviews in clinical 
laboratory sciences 28, 337-356 (1991). 
62. R. Baughman, Sarcoidosis. C. Lenfant, Ed., Lung Biology in Health Disease (Taylor and Francis 
Group, New York, NY, 2006), vol. 210. 
63. B. Baudin, [Angiotensin I-converting enzyme (ACE) for sarcoidosis diagnosis]. Pathologie-
biologie 53, 183-188 (2005). 
64. P. Alia, J. Mana, O. Capdevila, A. Alvarez, M. A. Navarro, in Scand J Clin Lab Invest. (Norway, 
2005), vol. 65, pp. 691-697. 
65. A. Floe, H. J. Hoffmann, P. H. Nissen, H. J. Moller, O. Hilberg, in Dan Med J. (Denmark, 2014), 
vol. 61, pp. A4815. 
66. A. Pietinalho, K. Furuya, E. Yamaguchi, Y. Kawakami, O. Selroos, The angiotensin-converting 
enzyme DD gene is associated with poor prognosis in Finnish sarcoidosis patients. Eur Respir J 
13, 723-726 (1999). 
67. A. Salazar, X. Pinto, J. Mana, Serum amyloid A and high-density lipoprotein cholesterol: serum 
markers of inflammation in sarcoidosis and other systemic disorders. European journal of 
clinical investigation 31, 1070-1077 (2001). 
68. E. Bargagli et al., Human Chitotriosidase: a Sensitive Biomarker of Sarcoidosis. Journal of 
Clinical Immunology 33, 264-270 (2013). 
69. Y. Zhang et al., in Respir Res. (England, 2013), vol. 14, pp. 18. 
70. E. Bargagli, A. Mazzi, P. Rottoli, Markers of Inflammation in Sarcoidosis: Blood, Urine, BAL, 
Sputum, and Exhaled Gas. Clinics in Chest Medicine 29, 445-458 (2008). 
71. C. P. Herbort, N. A. Rao, M. Mochizuki, International criteria for the diagnosis of ocular 
sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS). Ocular 
immunology and inflammation 17, 160-169 (2009). 
72. C. Febvay et al., Clinical features and diagnostic evaluation of 83 biopsy-proven sarcoid uveitis 
cases. The British journal of ophthalmology,  (2015). 
73. S. Miyoshi et al., COmparative evaluation of serum markers in pulmonary sarcoidosis. Chest 
137, 1391-1397 (2010). 
74. A. D. Vorselaars et al., ACE and sIL-2R correlate with lung function improvement in sarcoidosis 
during methotrexate therapy. Respir Med 109, 279-285 (2015). 
75. J. C. Grutters et al., Serum soluble interleukin-2 receptor measurement in patients with 
sarcoidosis: a clinical evaluation. Chest 124, 186-195 (2003). 
76. W. Wu et al., in J Transl Med. (England, 2014), vol. 12, pp. 152. 
77. G. Novelli, C. Ciccacci, P. Borgiani, M. Papaluca Amati, E. Abadie, Genetic tests and genomic 
biomarkers: regulation, qualification and validation. Clin Cases Miner Bone Metab 5, 149-154 
(2008). 
78. S. E. Calvano et al., A network-based analysis of systemic inflammation in humans. Nature 437, 
1032-1037 (2005). 
79. M. S. Rolph, M. Sisavanh, S. M. Liu, C. R. Mackay, Clues to asthma pathogenesis from 
microarray expression studies. Pharmacol Ther 109, 284-294 (2006). 
80. M. Selman, A. Pardo, N. Kaminski, Idiopathic pulmonary fibrosis: aberrant recapitulation of 
developmental programs? PLoS Med 5, e62 (2008). 
81. J. D. Herazo-Maya et al., Peripheral blood mononuclear cell gene expression profiles predict 
poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med 5, 205ra136 (2013). 
82. T. Zhou, T. Wang, J. G. Garcia, Expression of nicotinamide phosphoribosyltransferase-
influenced genes predicts recurrence-free survival in lung and breast cancers. Sci Rep 4, 6107 
(2014). 
83. A. A. Desai et al., A novel molecular signature for elevated tricuspid regurgitation velocity in 
sickle cell disease. Am J Respir Crit Care Med 186, 359-368 (2012). 
   
59 
 
84. S. P. Pitroda et al., Tumor endothelial inflammation predicts clinical outcome in diverse human 
cancers. PLoS One 7, e46104 (2012). 
85. M. K. Showe et al., Gene expression profiles in peripheral blood mononuclear cells can 
distinguish patients with non-small cell lung cancer from patients with nonmalignant lung 
disease. Cancer research 69, 9202-9210 (2009). 
86. M. J. Baine et al., Transcriptional profiling of peripheral blood mononuclear cells in pancreatic 
cancer patients identifies novel genes with potential diagnostic utility. PLoS One 6, e17014 
(2011). 
87. E. C. Baechler et al., Interferon-inducible gene expression signature in peripheral blood cells of 
patients with severe lupus. Proc Natl Acad Sci U S A 100, 2610-2615 (2003). 
88. A. Achiron, M. Gurevich, N. Friedman, N. Kaminski, M. Mandel, Blood transcriptional signatures 
of multiple sclerosis: unique gene expression of disease activity. Ann Neurol 55, 410-417 
(2004). 
89. R. H. Segman et al., Peripheral blood mononuclear cell gene expression profiles identify 
emergent post-traumatic stress disorder among trauma survivors. Molecular psychiatry 10, 500-
513, 425 (2005). 
90. D. F. Moore et al., Using peripheral blood mononuclear cells to determine a gene expression 
profile of acute ischemic stroke: a pilot investigation. Circulation 111, 212-221 (2005). 
91. J. E. Kontaraki, F. I. Parthenakis, E. G. Nyktari, A. P. Patrianakos, P. E. Vardas, Myocardial 
gene expression alterations in peripheral blood mononuclear cells of patients with idiopathic 
dilated cardiomyopathy. Eur J Heart Fail 12, 541-548 (2010). 
92. M. X. Pham et al., Gene-Expression Profiling for Rejection Surveillance after Cardiac 
Transplantation. N Engl J Med. 
93. M. P. Bihl et al., Progressive pulmonary sarcoidosis--a fibroproliferative process potentially 
triggered by EGR-1 and IL-6. Sarcoidosis Vasc Diffuse Lung Dis 23, 38-50 (2006). 
94. T. Zhou et al., in PLoS One. (United States, 2012), vol. 7, pp. e44818. 
95. W. S. Loke, C. Herbert, P. S. Thomas, Sarcoidosis: Immunopathogenesis and Immunological 
Markers. Int J Chronic Dis 2013, 928601 (2013). 
96. C. Kneitz et al., [Sarcoidosis in monozygotic twins]. Dtsch Med Wochenschr 120, 867-873 
(1995). 
97. B. A. Rybicki, M. J. Maliarik, L. M. Poisson, M. C. Iannuzzi, Sarcoidosis and granuloma genes: a 
family-based study in African-Americans. Eur Respir J 24, 251-257 (2004). 
98. A. M. Levin et al., Association of HLA-DRB1 with Sarcoidosis Susceptibility and Progression in 
African Americans. Am J Respir Cell Mol Biol 53, 206-216 (2015). 
99. J. P. Pandey, M. Frederick, TNF-alpha, IL1-beta, and immunoglobulin (GM and KM) gene 
polymorphisms in sarcoidosis. Hum Immunol 63, 485-491 (2002). 
100. S. Hofmann et al., Genome-wide association study identifies ANXA11 as a new susceptibility 
locus for sarcoidosis. Nat Genet 40, 1103-1106 (2008). 
101. F. Mrazek et al., Functional variant ANXA11 R230C: true marker of protection and candidate 
disease modifier in sarcoidosis. Genes Immun 12, 490-494 (2011). 
102. A. M. Levin et al., Association of ANXA11 genetic variation with sarcoidosis in African 
Americans and European Americans. Genes Immun 14, 13-18 (2013). 
103. M. D. Rossman et al., HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and 
whites. Am J Hum Genet 73, 720-735 (2003). 
104. J. Grunewald, A. Eklund, O. Olerup, Human leukocyte antigen class I alleles and the disease 
course in sarcoidosis patients. Am J Respir Crit Care Med 169, 696-702 (2004). 
105. M. M. Miretti et al., A high-resolution linkage-disequilibrium map of the human major 
histocompatibility complex and first generation of tag single-nucleotide polymorphisms. Am J 
Hum Genet 76, 634-646 (2005). 
106. A. Kishore et al., Whole-exome sequencing identifies rare genetic variations in German families 
with pulmonary sarcoidosis. Hum Genet 137, 705-716 (2018). 
   
60 
 
107. E. R. Gibney, C. M. Nolan, Epigenetics and gene expression. Heredity (Edinb) 105, 4-13 (2010). 
108. B. Schmidt et al., SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer 
based on bronchial aspirates. BMC Cancer 10, 600 (2010). 
109. I. V. Yang et al., DNA Methylation Changes in Lung Immune Cells Are Associated with 
Granulomatous Lung Disease. Am J Respir Cell Mol Biol 60, 96-105 (2019). 
110. E. D. Crouser et al., Differential expression of microRNA and predicted targets in pulmonary 
sarcoidosis. Biochem Biophys Res Commun 417, 886-891 (2012). 
111. C. Ascoli et al., A Circulating Micro-RNA Signature Serves as a Diagnostic and Prognostic 
Indicator in Sarcoidosis. Am J Respir Cell Mol Biol,  (2017). 
112. N. Kachamakova-Trojanowska et al., Molecular profiling of regulatory T cells in pulmonary 
sarcoidosis. J Autoimmun 94, 56-69 (2018). 
113. A. C. Nica, E. T. Dermitzakis, Expression quantitative trait loci: present and future. Philos T R 
Soc B 368,  (2013). 
114. Y. Chen et al., Variations in DNA elucidate molecular networks that cause disease. Nature 452, 
429-435 (2008). 
115. N. Casanova, Zhou,T., Gonzalez-Garay,M., Lussier, Y., Sweiss N., Ma, SF., Noth, I., Knox, K., 
Garcia, J.G.N., MicroRNA and Protein-Coding Gene Expression Analysis in Idiopathic 
Pulmonary Fibrosis Yields Novel Biomarker Signatures Predicting Survival. Translational 
Research,  (2020). 
116. L. Koth et al., Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with 
tuberculosis. Am J Respir Crit Care Med 184, 1153-1163 (2011). 
117. N. Casanova et al., Low Dose Carbon Monoxide Exposure in Idiopathic Pulmonary Fibrosis 
Produces a CO Signature Comprised of Oxidative Phosphorylation Genes. Sci Rep 9, 14802 
(2019). 
118. C. Swider et al., Presence of mRNA for interferon-gamma (IFN-gamma) in blood mononuclear 
cells is associated with an active stage I sarcoidosis. Clin Exp Immunol 100, 401-405 (1995). 
119. H. E. Lockstone et al., Gene set analysis of lung samples provides insight into pathogenesis of 
progressive, fibrotic pulmonary sarcoidosis. Am J Respir Crit Care Med 181, 1367-1375 (2010). 
120. S. Singla et al., Expression Profiling Elucidates a Molecular Signature for Pulmonary 
Hypertension in Sarcoidosis. Pulmonary Circulation NA,  (2016). 
121. S. Koo, F. M. Marty, L. R. Baden, Infectious complications associated with immunomodulating 
biologic agents. Infectious disease clinics of North America 24, 285-306 (2010). 
122. E. Gialafos et al., Relationship between tumor necrosis factor-alpha (TNFA) gene 
polymorphisms and cardiac sarcoidosis. In Vivo 28, 1125-1129 (2014). 
123. J. C. Grutters et al., Increased frequency of the uncommon tumor necrosis factor -857T allele in 
British and Dutch patients with sarcoidosis. Am J Respir Crit Care Med 165, 1119-1124 (2002). 
124. K. T. Amber, R. Bloom, U. Mrowietz, M. Hertl, TNF-α: a treatment target or cause of 
sarcoidosis? J Eur Acad Dermatol Venereol 29, 2104-2111 (2015). 
125. J. T. Rosenbaum et al., Parallel Gene Expression Changes in Sarcoidosis Involving the 
Lacrimal Gland, Orbital Tissue, or BloodParallel Gene Expression Changes in 
SarcoidosisParallel Gene Expression Changes in Sarcoidosis. JAMA Ophthalmology 133, 770-
777 (2015). 
126. L. L. Koth et al., Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with 
tuberculosis. Am J Respir Crit Care Med 184, 1153-1163 (2011). 
127. E. D. Crouser et al., Gene expression profiling identifies MMP-12 and ADAMDEC1 as potential 
pathogenic mediators of pulmonary sarcoidosis. Am J Respir Crit Care Med 179, 929-938 
(2009). 
128. C. Wei et al., Circulating miRNAs as potential marker for pulmonary hypertension. PLoS One 8, 
e64396 (2013). 
129. I. Sarrion et al., Role of circulating miRNAs as biomarkers in idiopathic pulmonary arterial 
hypertension: possible relevance of miR-23a. Oxid Med Cell Longev 2015, 792846 (2015). 
   
61 
 
130. Y. Xing et al., MicroRNA-30c contributes to the development of hypoxia pulmonary hypertension 
by inhibiting platelet-derived growth factor receptor beta expression. Int J Biochem Cell Biol 64, 
155-166 (2015). 
131. A. E. Hale, K. White, S. Y. Chan, Hypoxamirs in Pulmonary Hypertension: Breathing New Life 
into Pulmonary Vascular Research. Cardiovasc Diagn Ther 2, 200-212 (2012). 
132. J. Meloche et al., MiR-223 Reverses Experimental Pulmonary Arterial Hypertension. Am J 
Physiol Cell Physiol, ajpcell 00149 02015 (2015). 
133. M. Cao et al., MiR-23a regulates TGF-beta-induced epithelial-mesenchymal transition by 
targeting E-cadherin in lung cancer cells. Int J Oncol 41, 869-875 (2012). 
134. K. Zhong, K. Chen, L. Han, B. Li, MicroRNA-30b/c inhibits non-small cell lung cancer cell 
proliferation by targeting Rab18. BMC Cancer 14, 703 (2014). 
135. Y. Yang et al., The role of microRNA in human lung squamous cell carcinoma. Cancer Genet 
Cytogenet 200, 127-133 (2010). 
136. H. Liang et al., MicroRNA-223 delivered by platelet-derived microvesicles promotes lung cancer 
cell invasion via targeting tumor suppressor EPB41L3. Mol Cancer 14, 58 (2015). 
137. M. Ashburner et al., Gene ontology: tool for the unification of biology. The Gene Ontology 
Consortium. Nat Genet 25, 25-29 (2000). 
138. T. Zhou et al., Peripheral blood gene expression as a novel genomic biomarker in complicated 
sarcoidosis. PLoS One 7, e44818 (2012). 
139. J. T. Rosenbaum et al., Hypothesis: sarcoidosis is a STAT1-mediated disease. Clin Immunol 
132, 174-183 (2009). 
140. S. Muro et al., Expression of IL-15 in inflammatory pulmonary diseases. J Allergy Clin Immunol 
108, 970-975 (2001). 
141. H. S. Kim et al., Association of interleukin 23 receptor gene with sarcoidosis. Dis Markers 31, 
17-24 (2011). 
142. S. M. Sharma et al., Insights in to the pathogenesis of axial spondyloarthropathy based on gene 
expression profiles. Arthritis Res Ther 11, R168 (2009). 
143. H. M. diagnostics. (2019). 
144. R. Patro, G. Duggal, M. I. Love, R. A. Irizarry, C. Kingsford, Salmon provides fast and bias-
aware quantification of transcript expression. Nat Methods 14, 417-419 (2017). 
145. C. Soneson, M. I. Love, M. D. Robinson, Differential analyses for RNA-seq: transcript-level 
estimates improve gene-level inferences. F1000Res 4, 1521 (2015). 
146. A. Kamburov, U. Stelzl, H. Lehrach, R. Herwig, The ConsensusPathDB interaction database: 
2013 update. Nucleic acids research 41, D793-800 (2013). 
147. R. Valentonyte et al., Sarcoidosis is associated with a truncating splice site mutation in BTNL2. 
Nat Genet 37, 357-364 (2005). 
148. T. Zhou, Casanova N., Puladi, N., Wang, T., Lussier, Y., Kox, S.K., Garcia, J.G.N, in Scientific 
Reports. (2017). 
149. M. Katz, I. Amit, Y. Yarden, Regulation of MAPKs by growth factors and receptor tyrosine 
kinases. Biochim Biophys Acta 1773, 1161-1176 (2007). 
 
